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In the Western world, the lifetime risk for developing breast cancer in 
women is approximately 10%. Breast cancer is rare before the age of 30 after 
which the incidence rises until the menopausal age. After this the incidence 
remains relatively constant. The development of a breast carcinoma is a 
multifactorial process in which several reproductive and lifestyle factors play a 
role.1 
5-7% of all breast carcinoma patients present with distant metastases at 
the time of diagnosis2, but approximately 30% of patients with stage I, II, or III 
breast cancer harbour undetected microscopic distant deposits of metastatic 
carcinoma.3 It is still unclear which of these micrometastatic deposits make it 
to macrometastatic lesions. Selection for adjuvant chemotherapy is currently 
based on generally accepted prognostic and predictive factors including 
age, tumour size, histological grade, estrogen and progesteron receptor 
status, Her2/neu status, menopausal status and lymph node status.4,5 These 
factors perform relatively well in group based statistics, but for an individual 
patient it remains difficult to predict outcome. In the Netherlands adjuvant 
chemotherapy is given to approximately 90% of breast cancer patients younger 
than 35 years, to 55% of breast cancer patients 35-50 years of age, and to 20% 
of breast cancer patients 50-70 years of age (period: 1998 to 2002, n=8437; 
Netherlands Cancer Registry; http://iknl.nl). If chemotherapy is given, the risk 
for recurrent disease within 10 years is reduced with approximately 35% among 
women aged under 50 and approximately 20% among those aged 50-706,7, as 
confirmed by the 15 year follow-up analysis2, implying that a part of those 
patients would have survived without this toxic and expensive therapy. This 
underlines the importance of good prediction strategies to tailor treatment for 
each individual patient.8 
In recent years many microarray procedures have been developed which 
made it possible, from genome to protein, to assess multiple factors (e.g. 
the expression of many genes or proteins) per patient in one experiment and 
relate them to clinical endpoints. With these techniques it has become possible 
to differentiate between clinically relevant breast cancer subtypes and to 








In this thesis the tissue microarray (TMA) technique is used to assess 
the added value of novel protein markers that have been related to breast 
carcinoma to better predict outcome in (in-situ) breast carcinoma. The TMA 
technique was introduced by Kononen in 1998.9 Using this technique it has 
become possible to compile paraffin embedded material from up to 1000 donor 
paraffin blocks from different test samples (i.c. tumours) into one acceptor 
paraffin block. This enables highly efficient testing of large cohorts of tumours 
for the expression of one protein in one staining procedure. This in contrast 
to the other microarray methods in which the relative quantity of thousands 
of chromosomal regions, genes, SNPs or mRNA present in one tumour sample 
are assessed in a single test. In chapter 2 a critical overview of the different 
microarray techniques, including the TMA technique, is given. 
MUC1 (episialin, epithelial membrane antigen (EMA), CA15-3 antigen), 
a transmembrane glycoprotein expressed on the apical surface of normal 
glandular epithelial cells, has a controversial role in breast cancer.10,11 In vitro 
and some in vivo studies have described cell adhesion inhibition as well as 
increased metastatic and invasive potential of tumour cells by overexpression 
of MUC1.12-14 Other in vivo studies however, found a better outcome for 
patients overexpressing MUC115-17 or no relation between MUC1 expression and 
outcome at all.18-21 These divergent results might be explained by the different 
expression patterns for MUC1 that exist. The tissue microarray array technique 
is used in a series of in-situ ductal carcinomas (chapter 3) and invasive ductal 
carcinomas (chapter 4) to investigate a novel scoring system that is based on 
the location and pattern of MUC 1 expression in in-situ and invasive breast 
carcinomas. 
The introduction of a nation-wide breast cancer screening programme led 
to an increased incidence of in-situ ductal carcinomas (DCIS).22-24 Because DCIS 
does not always progress to invasive breast carcinoma some authors consider 
screen-detected DCIS to be overdiagnosis.25,26 Using the tissue microarray 
technique we studied pathological and biological differences between screen-
detected and interval DCIS hypothesizing that screen-detected is biologically 








branching- and coarse microcalcifications which are frequently associated with 
high grade DCIS. This is described in chapter 5. Although the introduction of the 
breast cancer screening programme led to a substantial decrease in advanced 
breast carcinoma and to a decline of breast cancer related mortality27, 36% of 
the tumours found in patients participating in the Dutch screening programme 
still emerge as interval carcinomas; clinically symptomatic carcinomas detected 
between two screening moments.28 There is discussion whether these interval 
carcinomas differ biologically from screen detected carcinomas and should 
perhaps be treated differently.29 In chapter 6 we investigated the biological 
aggressiveness of these interval carcinomas using the tissue microarray 
technique. 
Her2/neu receptor status is an important factor in the treatment of 
breast carcinoma as patients with Her2/neu receptor positive breast cancer 
have reduced mortality and recurrence rates when receiving combined 
adjuvant treatment with the anti-Her2/neu antibody trastuzumab and 
chemotherapy. Her2/neu receptor status is commonly assessed using 
immunohistochemistry.30,31 Immunohistochemistry for Her2/neu suffers from 
significant interobserver variation and poor interlaboratory reproducibility.32-35 
In recent years, rabbit monoclonal antibodies have been developed that should 
lead to more reliable test results than the previously used mouse monoclonal 
antibodies.36,37 In chapter 7 the potential of a novel rabbit monoclonal antibody 
against Her2/neu is tested using the tissue microarray technique.  
Finally, chapter 8 contains a general discussion on the most important 
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Microarray methods to identify factors determining breast  
cancer progression. Potentials, limitations, and challenges
Abstract
65 to 80 percent of the patients with breast cancer might not benefit from 
the adjuvant therapy they receive based on ‘classical’ markers used for 
the selection for adjuvant therapy. Therefore it is necessary to develop new 
markers that are able to tailor treatment for an individual patient. A number of 
microarray methods have been developed in recent years to accommodate this 
search for new factors that determine breast cancer progression. We give an 
overview of the most commonly used microarray methods to identify tumour 
progression markers (oligo- or cDNA arrays, CGH arrays, PCR arrays, and tissue 
microarrays). Their applications will be illustrated using the most influential 
examples from literature. The potentials, limitations and the related statistical 
analyses of each method are discussed. We conclude that microarray studies 
have led to an increase in the understanding of the complexity and diversity 
of breast carcinoma and have provided clinical relevant subgroups of breast 
cancer that may benefit from patient tailored treatment. Still, more extensive 
external validation and long-term follow-up will be necessary before such 
assays can be implemented into routine clinical practice. Most likely, these 
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1 Introduction
In the Western world, the life time risk for developing breast cancer in 
women is approximately 10%. 5-7% of patients present with distant metastases 
at the time of diagnosis, but 30-40% will develop metastases and die of the 
disease within 15 years.1 Currently, selection for adjuvant chemotherapy 
is based on generally accepted prognostic and predictive factors including 
age, tumour size, histological grade, hormone receptor status, Her2/neu 
status, menopausal status and lymph node status.2; 3 Although these factors 
perform relatively well in group based statistics, they poorly predict the 
outcome for the individual patient. Prediction in breast cancer is difficult 
because it is a very diverse disease comprising many biological subtypes 
that are all classified as invasive ductal breast carcinoma (breast carcinoma 
not otherwise specified (NOS)), because they cannot be added to one of the 
currently recognized specific breast cancer subtypes. Approximately 30% of 
patients with stage I, II, or III breast cancer harbour undetected microscopic 
distant deposits of metastatic carcinoma4, and it is still unclear which of these 
micrometastatic deposits make it to macrometastatic lesions. In the period 
1998 to 2002 adjuvant chemotherapy was given to circa 90% of breast cancer 
patients younger than 35 years, to 55% of breast cancer patients 35-50 years 
of age, and to 20% of breast cancer patients 50-70 years of age (n=8437; 
Netherlands Cancer Registry; http://www.ikcnet.nl/page.php?id=97) to treat 
micrometastases that go undetected at the time of diagnosis. If chemotherapy 
is given, the relative risk of reduction of relapse within 10 years is reduced 
with approximately 35% among women aged under 50 and approximately 20% 
among those aged 50-705, as confirmed by the 15 year follow-up analysis.1 
However these studies also show that substantial numbers of patients 
considered high-risk who did not receive adjuvant therapy in the old trials 
did not develop distant metastases, implying that many patients currently 
treated with adjuvant therapy are actually overtreated. This underlines the 
importance of good prediction strategies to tailor treatment for each individual 
patient.6 In recent years many microarray procedures have been developed 
which made it possible, from genome to protein, to assess multiple factors 
(e.g. the expression of many genes or proteins) per patient in one experiment 
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possible to differentiate between clinically relevant breast cancer subtypes and 
to search for new prognostic indicators in breast cancer.
In this review we give an overview of the currently used microarray 
methods and their applications will be illustrated using the most influential 
examples from literature. The potentials and limitations and the related 




The DNA microarray technique was first described by Fodor.7 Using this 
technique up to 50,000 known single stranded DNA fragments are immobilized 
at predefined spots on a solid surface.8 Using the natural quality of DNA to 
bind complementary DNA, study samples can be tested for gene expression. 
In this way, thousands of genomic or gene expression features of one tumour 
sample can be assessed in a single test.
2.1.2 cDNA array
cDNA arrays are the most commonly used microarrays. In this technique 
a microarray of oligonucleotides, cDNA (copy DNA), or mRNA sequences is 
compiled. Genes to be included are selected from a gene bank.9 cDNA from 
a test sample, usually generated from tumour mRNA, and reference cDNA, 
usually generated from mRNA isolated from multiple human cell lines, are 
labelled using two different detectable markers, e.g. a fluorescent dye (fig. 
1a). Both cDNAs are than mixed (fig. 1b). Single stranded DNA fragments from 
known genes of interest are immobilized on a solid surface, a microarray 
(fig. 1c). The mixture of test- and reference cDNA is then hybridized to this 
microarray (fig. 1d). After the excess of cDNA has been washed off, the 
intensity of the markers is read using a laser (fig. 1e). Relative expression of 
the test sample cDNA (compared to the reference cDNA) is calculated (fig. 1f). 







Microarray methods to identify factors determining breast  
cancer progression. Potentials, limitations, and challenges
2.1.3 Array Comparative Genomic Hybridization (array-CGH) 
In the development of many tumours chromosomal damage leads to gain 
or loss of genomic material. The increase of number of copies of the Her2/neu 
gene is the best known example of this. Using CGH technique it is possible 
to detect the number of copies of DNA sequences for the whole genome. 
Originally the copy number was mapped to metaphase chromosomes to assess 
the localisation, but in array-CGH artificial chromosomes from bacteria (BAC), 
vectors derived from bacteriophages, containing DNA sequences (cosmid or 
P1), or cDNA clones are immobilized on a glass surface and hybridized with 
a mixture of fluorescently labelled test and reference DNA. Using the same 
technique as in cDNA arrays the relative number of DNA sequence copies 
can then be calculated.11 Array CGH can also be performed on commercially 
available oligonucleotide platforms.
2.1.4 Single Nucleotide Polymorphism (SNP) microarray
SNPs are DNA sequence variations consisting of a single nucleotide. Certain 
SNPs are associated with an increased risk for disease. The technique of SNP 
microarrays is comparable to cDNA microarrays. Known SNPs are immobilized 
on a glass surface and a mixture of fluorescently labelled test and reference 
DNA is hybridized on this surface. Afterwards fluorescence intensities
are measured for each allele of each SNP.12 Using this technique it is also 
possible to assess loss of heterozygosity (LOH), a chromosomal mutation in 
which a complete allele is lost, as is frequently observed in breast cancer.
2.2 Applications
There are several applications for the microarray technique in breast cancer 
research. In the next section these applications will be discussed. 
2.2.1 Class definition
The first studies in breast carcinoma published using expression-arrays 
performed unsupervised clustering of microarray data. These analyses aimed 
to reveal whether previously unknown subtypes of breast carcinoma can be 
recognized based on differences in expression profile. The first and probably 
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representing 8102 genes to subtype 65 breast carcinomas into four distinct 
subtypes, of which two were previously unknown: an oestrogen receptor 
(ER) positive group, a normal breast like group that highly expressed genes 
seen in adipous- and other non-epithelial cell types, an ErbB2 positive group 
over expressing several genes on the ErbB2 amplicon, and a basal like group 
overexpressing keratins 5 and 17, laminin and fatty acid binding protein 
7.13 Later, the ER positive group was divided into at least two subgroups: a 
luminal ‘A’ subgroup, characterized by a high expression of the ER α gene, 
GATA binding protein 3, X-box binding protein 1, trefoil factor 3, hepatocyte 
nuclear factor α and LIV-1, and luminal ‘B and C’ subgroups expressing low 
to moderate levels of these luminal specific genes.14 It was shown that these 
‘molecular portraits’ are maintained throughout the metastatic process of 
breast cancer.14; 15 Using a supervised clustering method (see statistics section 
5.2.3) others found gene sets that were able to divide patient groups by ER 
status16; 17 and axillary lymph node status16 suggesting a different biological 
background for these groups. In a genome-wide association study by 
genotyping 528,173 SNPs in 1,145 postmenopausal women with invasive breast 
cancer and 1,142 controls four SNPs in intron 2 of FGFR2, a region encoding a 
tyrosine kinase receptor commonly associated with breast cancer, were found 
that were highly associated with breast cancer. This association was verified 
in the same study using 1,776 affected individuals and 2,072 controls from 
three additional studies.18 A whole genome screen of 81 breast carcinoma 
samples from 19 non-BRCA1/2 breast cancer families using 4720 genome 
wide SNPs was performed and six regions on chromosomes 2, 3, 4, 7, 11 and 
14 were identified as candidates to contain genes involved in breast cancer 
susceptibility.19
Using array-CGH, from a group of 36 patients with a proven BRCA1 mutation 
and 30 patients with an elevated breast cancer risk (independent bilateral 
breast carcinomas), a molecular classifier was built that detected 84% of BRCA1 
tumours.20
2.2.2 Survival prediction
The next logical application of microarrays was to use the retrospectively 
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by Perou et al13, Sorlie was able to predict prognosis in a group of 78 breast 
carcinoma patients.14 Mainly the basal like type of breast carcinomas was 
associated with poor prognosis. 
Another important study was performed by Van ‘t Veer et al who developed 
a 70 gene set that was able to predict the development of metastasis in 
follow-up in a group of 98 young patients consisting of 34 patients that had 
developed metastasis within 5 years, 40 patients that continued to be disease 
free after 5 years, 18 patients with a BRCA-1 mutation and 2 patients with 
a BRCA-2 mutation.21 This 70 gene signature was later validated in a group 
of 295 early stage breast carcinoma patients, partly consisting of the group 
used to train the model. Using this signature outcome could be predicted 
more accurately than using standard parameters.22 An other gene set that was 
extensively validated comes from Wang et al. In a group of 286 node negative 
breast carcinoma patients that had not received adjuvant therapy a gene set 
containing 76 genes of which 60 genes came from ER-positive patients and 
16 genes from ER-negative patients was developed that was able to identify 
patients who developed distant metastases within 5 years. This gene set was 
validated in the same study using an independent testing set. In this set 
the gene set had a high sensitivity (97%) and a mediocre specificity (48%).23 
This gene set was validated externally in two independent groups of 180 and 
198 node negative breast carcinoma patients, not receiving adjuvant chemo-
therapy.24; 25 In these studies comparable prognostic groups as in the initial 
studies were found. In a similar manner as the examples given above others 
developed and validated gene sets that are able to predict survival of specific 
patient groups.23; 26-31 The outcomes of those studies were comparable to those 
described above. 
2.2.3 Response Prediction 
Microarray studies have been conducted on the role of gene expression 
profiles in the prediction of response to therapy. All these studies however, 
were performed in very small study groups which might have confounded 
their results. From a group of 24 advanced breast carcinoma patients a gene 
expression profile was derived that predicted the response to neoadjuvant 
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an independent set of 6 tumours. From a group of 24 advanced breast 
carcinoma patients, a gene-set predicting pathological complete response after 
neoadjuvant paclitaxel and fluorouracil, doxorubicin and cyclophosphamide 
chemotherapy was derived and validated in a group of 18 advanced breast 
carcinoma patients.33 From 60 patients treated with adjuvant tamoxifen 
monotherapy, a gene set was derived predicting the response to therapy. This 
gene set consisted of only two genes.34
3 Polymerase Chain Reaction (PCR)-array
3.1 Technique
‘Real time’ quantitative reverse transcription (qRT)-PCR techniques which 
are commonly used for high throughput applications are based on the concept 
of detecting accumulating PCR products from genetic regions of interest in test 
samples.35; 36 RNA from tumour cells is isolated and using reverse transcriptase 
converted into double stranded DNA (fig. 2a). This DNA is denatured yielding 
single stranded DNA (fig. 2b). Next primers specific to the 3’ and 5’ ends of the 
genetic region of interest are allowed to anneal to the single stranded DNA (fig. 
2c). Taq polymerase binds to the primer and extends to the end of the DNA 
strand synthesizing a new complementary DNA strand (fig. 2d), yielding double 
stranded DNA. After this the cycle is repeated. SYBR Green, a fluorescent dye 
that has low fluorescence in the absence of double stranded DNA, and high 
fluorescence in presence of double stranded DNA is added. As the PCR process 
proceeds the amount of fluorescence, and thereby indirectly the amount of 
double stranded DNA, is measured in ‘real time’ at each amplification cycle. 
The amplification cycle at which the fluorescent PCR product is first detectable 
is called the threshold cycle (fig. 2e). This is an extremely accurate measure for 
the quantity of the target gene in the test sample. This quantity can than be 
compared with that of other test samples and ‘normal’ controls. 
3.2 Applications
3.2.1 Subtyping
Ahr et al applied a PCR assay containing 15 genes from a prior microarray 
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been described or which were considered useful as surrogate markers for 
proliferation (MKi67, PoloLikeKinase), IFN inducible genes (STAT1), stromal cells 
(DDR2) and vascularization (VEGFR), to a panel of 94 specimens (containing 73 
breast carcinomas) and were able to identify a subgroup of breast carcinomas 
associated with poor clinical characteristics.37 Using a PCR array containing 
47 genes selected from literature on a group of 199 breast carcinomas others 
identified a subgroup (designated ‘subgroup 7’) of carcinomas with a low 
recurrence risk.38 The results from the DNA microarray study by Perou13 were 
confirmed in a group of 123 breast samples using a PCR array containing 53 
genes.39 
3.2.2 Survival prediction
Paik et al developed a 21 gene PCR assay (Oncotype DX™) from a candidate 
set of 250 genes, selected from literature and the results of cDNA studies 
which included 16 cancer-related genes and 5 reference genes by using the 
results from three independent studies compromising a total of 447 patients. 
Using the results from this assay they calculated a Recurrence Score (RS). This 
RS represents the risk of developing distant recurrences in follow-up.40 In the 
same study this assay was also successfully used to predict outcome in an 
independent group of 668 node-negative tamoxifen treated breast carcinoma 
patients. However, when applied in a group of 149 patients with node-negative 
breast cancer who had not received adjuvant systemic therapy the assay was 
unable to predict distant disease recurrence.41
3.2.3 Response prediction
Like the mRNA/cDNA microarray studies, the PCR-assay introduced by Paik 
et al40 was later used successfully to predict the response to chemotherapy in 
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4 Tissue microarray
4.1 Technique
The tissue microarray (TMA) technique was introduced by Kononen in 1998.43 
Using this technique it is possible to compile paraffin embedded material from 
up to 1000 donor paraffin blocks from different test samples (i.c. tumours) 
into one acceptor paraffin block. This enables highly efficient testing of large 
cohorts of tumours for the expression of one protein in one staining procedure. 
This in contrast to the microarray methods in which the relative quantity of 
thousands of chromosomal regions, genes, SNPs, or mRNA present for one 
tumour sample is assessed in one single test.
The construction of a TMA starts by selecting the most representative 
tumour spot (fig. 3a) on the donating paraffin block using a Haematoxylin & 
Eosin (H&E) stained section for orientation purposes (fig. 3b). Most authors use 
a manual tissue arraying instrument (Beecher Instruments, Silver Springs, MD, 
USA) to take a number of core punches from the donating paraffin block (fig. 
3c) and arraying them into a predestined spot in the new acceptor paraffin 
block (fig. 3d). There is discussion on the number of tumour cores that should 
be included in a TMA to be representative for a tumour, especially because 
breast tumours tend to be very heterogeneously. It was shown that only two 
0.6mm cores need to be included in an acceptor block to be representative 
for a whole tumour in more than 95% of the cases.44 Most authors however 
include three or four tumour cores in an acceptor block.45 After arraying the 
tumour cores in the acceptor block most authors note the localisation in 
an Excel worksheet for later reference. From the recipient block standard 3 
um microtome sections can be cut (fig. 3e). On these sections all commonly 
applied immunohistochemistry and in-situ techniques can be performed.
4.2 Applications
In general, TMA is not suitable for testing on a single patient basis. However, 
in retrospective studies, TMAs can be applied to select for which limited set 
of proteins the expression should be determined to be the most informative 
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4.2.1 Class definition
Using immunohistochemistry for the key markers of the Perou study46 
defining the breast carcinoma subtypes two different studies were able to 
confirm these subtypes on FFPE material embedded in TMAs containing 107 
and 1,076 cases respectively.47; 48 
Zhang et al performed immunohistochemistry for 7 breast carcinoma related 
genes (ER, PR, c-ErbB2, p53, Cox-2, VEGF and PDGF) on a TMA containing 
97 tumours. Using unsupervised clustering they found an ER+ and an ER- 
subgroup.49
4.2.2 Survival Prediction
Makretsov et al presented a series of 438 breast carcinomas arrayed in a 
TMA.50 They performed immunohistochemistry for a panel of 31 markers related 
to breast cancer. This panel was gathered from the results the microarray 
studies. By performing hierarchical clustering on the expression data of these 
31 genes a gene set of 11 genes was compiled, that gene set was able to 
predict different prognostic classes in breast carcinoma independent of lymph 
node metastasis, tumour size, and tumour grade in multivariate analysis. 
Using a TMA consisting of over 600 breast tumours van de Rijn et al, showed 
that a subgroup of breast carcinomas expressing cytokeratins 17 and 5/6 was 
correlated with poor prognosis.51 
4.2.3 Response Prediction
Using a TMA, Tovey et al showed in a group of 402 ER positive patients 
treated with tamoxifen that a group of HER1-3-positive and/or PR-negative 
patients were significantly more likely to have an early relapse under 
tamoxifen treatment in univariate and multivariate analysis.52 In a series of 
178 node positive breast carcinoma patients, treated with doxorubicin based 
chemotherapy, Park et al used a TMA to assess Cox-2 expression in this 
group of patients. Patients with a tumour expressing Cox-2 had a significantly 
decreased over overall and disease-free survival when compared to patients 
with tumours that did not express Cox-2. The authors conclude that Cox-2 
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5 Statistics
5.1 General
One thing all gene expression profiling experiments have in common is the 
vast amount of data points generated. Authors use several statistical tools, 
with a varying degree of complexity, to look for patterns in these data. For 
tissue microarray technique, multiple samples from one tumour must generate 
one final result. When a gene expression profile has been discovered it needs 
to be validated. In this section methods for data reduction and validation of 
gene expression experiments will be discussed. 
5.2 Data reduction
5.2.1 TMA
Because multiple cores from one tumour are often incorporated in a TMA, 
data from TMA experiments usually features multiple scores from one tumour 
sample. After assessing that each of those cores consists of representative 
tumour material, these scores need to be combined. Several rules can be 
applied to combine multiple scores. One could average the scores, or take the 
highest or lowest score. Which rule applies best is dependent on the biological 
properties of the marker stained for. If any degree of loss of a certain marker 
in a tumour is biologically relevant it is best take the lowest score, but for a 
marker of proliferation, e.g. Ki-67, it would be best to take the average score. 
TMA combiner, a computer program available free of charge, is able to combine 
multiple scores noted in an Excel worksheet by applying one of the combining 
rules.54
5.2.2 Unsupervised clustering
In unsupervised clustering data is divided into clusters. Two approaches 
are commonly used. In hierarchical clustering gene expression for each of 
the study samples is calculated and samples are arranged on similarities in 
the gene expression profile. This a graphically represented in a dendrogram. 
Afterwards this dendrogram can be divided in two or more clusters. In k-means 
clustering the number of clusters is predefined. For each of the samples a 
gene expression is calculated. Each of the samples is than added to one of the 
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from the others to define specific subgroups in the study population. A good 
example of unsupervised clustering is the study by Perou where a group of 
ductal carcinomas was divided and new classes were found.13 
Unsupervised clustering will always generate several clusters it is therefore 
important to relate the outcome of a cluster analysis to clinical data and to 
perform a validation of the model.55  
5.2.3 Supervised clustering
In supervised clustering two or more groups are predefined before a 
cluster algorithm is used, e.g. patients that will and will not develop distant 
metastasis in follow-up. Between these two groups a clustering algorithm will 
calculate which genes best differentiate both groups. The van ‘t Veer study is 
an example of a study where supervised clustering was used.21
A problem with supervised clustering is over-fitting. Most studies use a 
small sample of the total study group to train a cluster algorithm and use the 
remaining part of the study group to test this algorithm. When the algorithm 
build on the small training group is perfectly fitted to this small group it will 
lose predictive power for the remaining part of the group.55
5.3 Validation
One of the largest problems of gene expression studies is multiple testing; 
because the number of samples included in a study is small compared to 
the enormous number of genes tested, a large number of the significantly 
tested genes may have been found purely by chance. Because genes in a gene 
expression profile are not always independent of one another it is difficult to 
correct for multiple testing.56 To test if a gene set found in a ‘training’ group 
also applies to other groups it is necessary to validate such a gene set. Several 
methods of internal and external validation are used. 
5.3.1 Internal validation
In internal validation (a part of) the study group is used to validate the 
model. 
In split sample validation half of the study population is used to ‘train’ a 
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half of the group. Because the number of samples in the gene expression 
study is usually limited, the disadvantage of this method is clear: both 
the training and the testing group comprise a relatively low number of 
samples.57 To avoid this problem several methods of cross-validation have 
been developed. In cross-validation gene profiles are trained using the study 
group minus one (“leave-one-out” cross validation) or a few of the samples 
and afterwards using the samples left out to test the profile (so-called ‘boot-
strapping). This is repeated until all the samples have been in the training and 
testing group. For each of the tests a prediction error is calculated. Afterwards 
these prediction errors are totalled. This total represents the fitting of the 
model.58; 59 Because the ‘training’ and the ‘test’ set are not independent of one 
another this method of validation may lead to biases in the model.56
5.3.2 External validation
The objective of external validation is to determine whether use of a 
completely specified diagnostic classifier for therapeutic decision making in 
a defined clinical context results in patient benefit.57 To make it possible to 
easily interpret and to verify or validate microarray data, standards for the 
presentation of microarray data have been developed, the MIAME (Minimal 
Information About a Microarray Experiment).60 To perform an optimal external 
validation some rules apply to the study group used: (a) the inclusion criteria 
of the patients should be the same as the group in which the profile was 
trained, (b) the clinical end point of the study should be the same as the 
initial study and (c) exactly the same prediction rule as used in the initial 
study should be used in the validation study. This includes the genes selected, 
the method used to measure their expression, the equation and the cut-off 
point for the different classes of the initial study.61 External validation studies 
should focus on the ‘low-risk’ class of the expression profile, as this is the 
group of patients that will possibly benefit from omitting therapy. Because this 
group is often small and has to be randomly divided in a treated and a non-
treated group, large studies are necessary. Also a long follow-up is necessary 
to show a difference in survival between both groups with already low 
recurrence risk.57 Therefore if possible it would be useful to plan such studies 
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trails.57 The multigene PCR assay of Paik was validated in this manner.40
Problem of such studies are the often out-dated adjuvant therapy regimes 
used in these patient groups, which confound the results of such studies. 
In the multicentre phase III trail TAILORx (Trial Assigning IndividuaLized 
Options for Treatment (Rx)) trial this PCR array will be prospectively tested. 
Patients with axillary lymph node negative breast cancer and a Oncotype DX™ 
recurrence score of 11-25 are randomly assigned to receive combined adjuvant 
chemotherapy and hormal therapy or adjuvant hormal therapy alone  
(http://www.cancer.gov/clinicaltrials/ECOG-PACCT-1). 
The gene set of Perou was validated by Sorlie on independent datasets, 
but not all the genes assessed in the initial study were available for the 
independent datasets. Also the clinical end-points for the independent 
datasets was different.62 The 70 gene model of van ‘t Veer was validated by 
van de Vijver in a study group that partly consisted of patients used in the 
training model, therefore this validation was not entirely independent and 
might have been biased.63 However, this model was retrospectively validated in 
an independent group, with similar results.64 The MINDACT (Microarray In Node 
negative Disease may Avoid ChemoTherapy) trial is a multicentre, prospective, 
phase III trial in which 6000 node negative patients will be included.65 For 
all patients included a risk profile will be calculated using ‘classical’ clinico-
pathological markers and using the 70-gene signature. In cases where both 
methods are discordant a patient is randomly assigned to a treatment decision 
based ‘classical’ clinico-pathological markers or the 70-gene signature. The aim 
of this study is a reduction of 10-15% of chemotherapy treatment in the low 
risk group.
6.1 Discussion and future directions
The development of array comparative genomic hybridization, gene 
expression profiling, and the tissue microarray technique has led to a 
revolution in how to classify breast tumours and how to classify and predict 
prognosis and response to therapy. None of the techniques described in this 
review is likely to be superior to the other, but rather complementary. While 
DNA microarrays are useful to assess a large number of genes in a small 
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validate the ‘key’-markers from DNA microarray studies in large patient groups. 
Nevertheless, most attention has been paid to gene expression profiling 
for clinical purposes to discriminate between low versus high risk tumours 
which might guide decision making for administration of adjuvant therapy 
as is currently being tested in clinical trials.65 Most strikingly, there is no or 
hardly any overlap between the gene sets tested in the different available 
predictive or prognostic signatures.66 Partially, this can be explained by the 
use of different gene expression profiling platforms. Even within a single 
dataset a multitude of signatures can be selected that perform equally well 
with respect to prognosis prediction. This was illustrated by Ein-Dor et al. who 
showed that the selection of patients to be included in the training set of the 
model very much defines the gene list.67 This was supported by Michiels et 
al who randomly sampled 500 groups of 78 patients from the Van ‘t Veer’s 
group of patients and calculated a gene expression profile for each of those 
groups using the same technique and the same genes van ‘t Veer et al used 
to calculate their profile. Only 14 of the genes ‘original’ gene expression profile 
appeared in more than 50% of the 500 calculated profiles and 10 genes that 
were not in the van ‘t Veer profile also appeared in more than 50% of the 
500 profiles.59 This might be explained by the way test samples are selected, 
as most of the gene expression profiles were drawn from and optimised for 
specific patient groups (e.g. young, node negative patients). This might lead 
to applicability only in these specific groups of patients, although in a recent 
analysis the Amsterdam profile appeared to perform equally well for patients 
with 1-3 positive lymph nodes.68 On the other hand, the selection of test 
samples comprising a consecutive series of young breast cancer patients with 
lymph node negative disease comprised a few BRCA-1 gene mutation carriers 
which did not affect the prognostic power of the test.21 In addition, Fan et 
al published a study in which five gene expression profiles were applied to 
the same dataset.69 The outcome predictions of the various models showed 
overlap, suggesting that although different genes are included in the models, 
the biological subgroups predicted by those genes are equal and that these 
different signatures are sufficiently robust to predict outcome. In addition, the 
expression signatures might perform relatively well because the interobserver 
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result in suboptimal prognosis prediction. 
Most predictive models derived from gene expression profiles do not 
provide an improved prognostic classification when compared to the ‘classical’ 
prognostic factors.70 It has been shown on the 234 patients from van de 
Vijver et al who were not in the first study that the gene signature added a 
moderate but not significant improvement in predictive accuracy when added 
to the prognostic factors: age, nodal involvement, estrogen receptor status 
and tumour grade.71 Another study compared five gene expression profiles and 
found that these profiles showed prognostic value independent of classical 
prognostic indicators, including grade, but that it is not clear that these 
models provide more prognostic information than the combination of currently 
available markers.72
A study by Sun et al, who compared the predictive power of clinical 
prognostic indicators and gene expression profiles alone, with a combination 
of clinical prognostic indicators and a gene expression profile in predicting the 
development distant metastases in breast cancer patients. The combination of 
both methods gained a far higher power.73 We therefore believe that the use of 
the novel prognostic indicators as discussed in this review, should rather be 
complementary to ‘classical’ prognostic indicators instead of replacing these 
indicators. 
There are some practical issues that should to be resolved before wide-
scaled introduction of DNA microarrays can take place, as: the RNA in 
formalin fixed paraffin embedded material is to fragmented to be used in 
gene expression profiling. To prevent this, sampling fresh tumour tissue for 
cryopreservation shortly after surgery is required.
Some therefore argue that PCR arrays have advantages over DNA microarrays 
in daily clinical practice, because this an easily reproducible method that 
requires only a limited amount of tumour tissue.74 Because PCR array can be 
performed on formalin fixed paraffin embedded (FFPE) material, no tumour 
tissue is lost for freezing.34; 40; 75 However, with this type of array the expression 
of only a small number of genes can be assessed. DNA microarrays and PCR 
arrays measure the total amount of a certain gene product in a cell at the 
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mRNA levels do not always parallel the level of protein expression. Moreover, 
arrays assessing the level of mRNA expression do not provide any information 
about the biological activity of the encoded proteins, especially when proteins 
are involved in signal transduction. The advantage of TMA technique is that it 
is not only applicable on FFPE material, that it enables subcellular localization 
of the encoded protein as the histological context is maintained. This makes it 
possible to determine if the product has any biological relevance. For instance, 
E-cadherin has a well established function when expressed at the cellular 
membrane. The function of cytoplasmically expressed E-cadherin is unclear. In 
a TMA it is possible to differentiate between those two expression patterns. 
Because of the labour intensive scoring of TMAs the amount of genes scored 
using a TMA is relatively low. The scoring of IHC-staining by hand causes intra- 
and inter-observer variability. TMA evaluation is limited to known genes with 
an antibody available, therefore no new genes can be discovered using this 
method. In addition, a TMA is of no advantage on a single patient basis during 
the diagnostic work-up of surgically removed breast tissue.
A technique that is currently under way is ChIP (chromatin 
immunoprecipitation) on chip technique, which provides an assay for the 
genome-wide location and functional analysis of DNA-binding proteins.76 
DNA-binding proteins bind to specific sites at the genome to regulate genome 
expression and maintenance, thereby regulating for example RNA synthesis or 
allowing cells to move through the cell cycle. Using ChIP on chip technology 
specific DNA-binding proteins can be assessed across the genome of many 
samples. Because this is a functional analysis, it is the most precise method 
of detecting DNA activation. Another emerging technique is the application of 
protein arrays, where it is possible to assess the expression of proteins on a 
similar manner as a DNA microarray.77 Both methods have to our knowledge not 
been applied in breast cancer research yet. 
In conclusion we believe that microarray studies, by discovering patterns 
in gene expression of breast carcinomas, should be used to gain insight in 
the biological pathways of breast cancer progression, and that well validated 
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markers, may be combined with ‘classical’ prognostic indicators for use in 
daily clinical practice. However, the exact clinical value for the gene profiles 
described in this article remains to be established. Not until these profiles are 
validated in well designed prospective clinical trials such as the MINDACT65 
and TAILORx, treatment decisions should be made based on gene expression 
profiling results. In the mean time, the refinement of microarray techniques 
including more sophisticated data mining and statistical analysis methods 
to establish biologically and clinically relevant signatures is still ongoing at 
high speed. This will improve unraveling the factors determining tumour type, 
prognosis, and response to treatment, including the factors responsible for 
constitutional or acquired resistance to conventional or targeted adjuvant 
therapy. Eventually these developments will enable the most optimal medical 
treatment for each individual breast cancer patient. 
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Abstract
Aims: To evaluate five predefined types of MUC1 expression in a series of 
cases with pure ductal carcinoma in situ (DCIS), and to investigate the relation 
between the pattern of MUC1 expression and co-expression of biological 
markers, clinico-pathological parameters and prognosis. 
Methods and Results: With a manual tissue arrayer, 92% (n=80) of the 
87 DCIS samples were successfully targeted. Slides were stained for MUC1, 
estrogen receptor (ER), progesterone receptor (PR), Her2/Neu, p53, and 
cyclin D1. Entire membrane expression was related with Her2/neu negativity 
(p=0.042). Apical membrane expression was associated with low grade 
(p=0.027), Her2/neu negativity (p=0.014), and PR positivity (p=0.005). Focal 
cytoplasmic expression was related with high grade (p=0.006). Diffuse 
cytoplasmic expression was associated with high grade (p=0.004), large 
tumour size (p=0.046), Her2/neu positivity (p=0.042), and cyclin D1 positivity 
(p=0.002). On the basis of former analyses the four patterns were classified 
as membrane- or cytoplasmic expression. In multivariate analysis MUC1 
cytoplasmic expression (Hazard Ratio 8.5, 95% Confidence Interval 1.0-73.0, 
p=0.04) was the only independent predictor of local recurrence. 
Conclusions: Four patterns of MUC1 expression are recognized in DCIS that 
suggest a relation with functional differentiation and can be divided into 
two types that are clinically relevant and could therefore be helpful in the 







The expression pattern of MUC1 (EMA) is related to tumour characteristics 
and clinical outcome in 'pure' ductal carcinoma in situ of the breast
Introduction
MUC1, also known as epithelial membrane antigen (EMA) or episialin, is 
a mucin-like transmembrane glycoprotein encoded by a gene on 1q21 and is 
expressed at the luminal surface of the epithelial cell membrane of normal 
breast ducts1. In vitro and in vivo studies have indicated that increased 
MUC1 expression can facilitate the process of metastasis by modification of 
intercellular adhesion.2-5
Although MUC1 expression patterns have been extensively studied in 
invasive ductal carcinoma, there are only a few analyses of the MUC1 
expression patterns in ductal carcinoma in situ (DCIS). Diaz et al6 described 
luminal, membranous, and cytoplasmic staining of MUC1 in DCIS. In that 
study cytoplasmic staining was associated with a higher grade. In a study 
by Mommers et al7 three different patterns of MUC1 expression in DCIS are 
described: staining of the apical (luminal) membrane, staining of the entire 
cell membrane and cytoplasmic staining. In that study membrane expression 
of MUC1 was related with high grade, although cytoplasmic expression was not 
evaluated being too difficult to distinguish from background staining.
Detection of MUC1 by immunohistochemistry is strongly influenced by 
the degree of glycosylation and the primary antibody used, as most MUC1 
antibodies bind the extracellular mucin-like domain and are sensitive to the 
degree and make-up of glycosylation of their antigenic site.8 For that reason, 
we used an antibody that is robust in binding MUC1 because it is almost 
insensitive to the degree of glycosylation of MUC1.9
Recently, we identified five patterns of MUC1 expression in invasive 
breast carcinomas in a parallel study and it is likely that these patterns have 
clinico-pathological relevance (unpublished observations). In this study the 
classification of MUC1 was applied to a set of pure ductal carcinoma in situ 
tumours arranged in a tissue microarray (TMA) in order to determine the 
relation of these MUC1 expression patterns with the expression of established 
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Materials and methods
Patients and tumors
Patients were selected on the availability of the original pathological 
slides and sufficient paraffin embedded tissue. Eighty-seven patients were 
included in the study and all patients had been treated for pure DCIS between 
July 1992 and October 2001. Clinical and pathological data of patients were 
reviewed from pathology reports, radiology reports and medical charts and 
follow-up was evaluated by the reports of outpatient clinic visits. Radiological 
and histo-pathological characteristics have been reported previously.10 The 
patients characteristics are depicted in Table 1. Median age was 57.7 (range 
36.8-77.5 years). Fifty-two cases (59%) were detected by the National Screening 
Programme for Breast Cancer. Forty-eight patients had been treated with 
mastectomy and 39 patients with breast conserving surgery (BCS), including 
post-operative radiotherapy in 20; none received adjuvant endocrine therapy. 
The median follow-up time for all patients was 39 months and ipsilateral 
recurrence was recorded as DCIS or invasive carcinoma.
Tissue microarray construction
Slides from all blocks were evaluated for representative areas with DCIS 
and tissue microarrays were prepared as described earlier.11 In brief, the most 
representative area of DCIS was marked on the original hematoxylin- and 
eosin (H&E) stained section. With this marked section as an orientation, three 
0.6 mm punches were taken from the selected area in the donor blocks and 
mounted in a recipient block containing approximately 110 biopsies, using 
a manual tissue microarray device (Beecher Instruments, Silver Springs, MD, 
USA). Out of 87 cases, representative tissue cores were obtained in 80 cases 
(92%) and acceptable immunohistochemistry (at least one of the three cores 
was stained sufficiently) was achieved in 69 (79%) cases for p53, 70 (80%) 
cases for cyclin D1- and PR- staining, 73 cases (84%) for ER- and MUC1 staining 
and 80 cases (92%) for Her2/neu staining.
Immunohistochemistry
For immunohistochemistry, 3 μm sections of the tissue microarrays were 
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rehydrated through changes of graded ethanol from 100% to distilled water. 
Antibodies and antigen retrieval methods are summarised in Table 2. The 
endogenous peroxidase reaction was blocked by incubating the sections 
in 3% perhydrol for 30 minutes. Primary antibodies were diluted in PBS 
containing 1% Bovine Serum Albumin and incubated at room temperature 
for 1 hour. Samples were then washed in PBS and incubated with secondary 
and tertiary antibodies. For visualization of the antibody-antigen complex, 
the diaminobenzidine tetrahydrochloride/ peroxidase reaction was used. 
After a final wash with distilled water, counterstaining was performed with 
hematoxylin. Sections were dehydrated through rising concentrations of 
ethanol and mounted.
Evaluation of immunohistochemical staining
All slides stained for molecular markers were read by one author (MdR) 
and checked by another (JW). ER, PR, p53, and cyclin D1 were graded based 
on the percentage of cells showing positive nuclear staining in the ducts 
with DCIS. ER, PR and cyclin D1 were considered positive if nuclear staining 
was present in >10% of the cells, and p53 was considered positive in case of 
more than 30% positively stained nuclei. Her2/neu expression was graded as 
recommended by the manufacturer’s scoring guidelines: 0: no staining at all or 
membrane staining in <10% of the tumour cells; 1+: a faint/barely perceptible 
partial membrane staining in >10% of the tumour cells; 2+: weak to moderate 
complete membrane staining in >10% of the tumour cells; 3+: strong complete 
membrane staining in >10%. Her2/neu was considered positive if the score was 
3+. For the classification of the MUC1 expression, 5 expression patterns were 
used as illustrated in figure 1. MUC1 expression was considered positive if 
there was staining in >10% of the tumour cells. 
Statistical analysis
Chi-square tests were performed in order to assess the relation between 
the types of MUC1 expression and biological markers and clinico-pathological 
parameters. After performing the chi-square tests the four types of MUC1 
expression could be reduced to two pathologically and biologically different 
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local recurrence was investigated in univariate and multivariate analysis. 
Univariate analysis and multivariate analysis were performed by Cox 
regression. The elimination of variables in a stepwise manner identified the 
statistically significant predictors in multivariate analysis. A p-value of <0.05 
was considered as significant. All calculations were performed with SPSS 12.01 
(SPSS inc., Chicago, IL, USA).
Results
Immunohistochemical detection of MUC1
MUC1 expression patterns are exemplified in Figure 1. MUC1 was expressed 
in all cases (100%, n=73). Predominant entire membrane expression was 
present in 20 cases (27%). Apical membrane staining was seen in 23 cases 
(32%). Focal cytoplasmic staining was described in 39 cases (53%). In most 
cases (n=58, 84%) diffuse cytoplasmic staining was present. Inside-out staining 
was not found. The majority of the DCIS (n=57, 78%) displayed more than 
one type of MUC1 expression. The most frequently pure pattern of staining 
was diffuse cytoplasmic immunoreactivity (n=12, 16%). The most frequent 
promiscuous pattern of staining was the association between focal cytoplasmic 
and diffuse cytoplasmic expression (n=30, 41%). 
MUC1 expression and clinico-pathological characteristics 
The association between MUC1 expression and clinico-pathological 
parameters is outlined in Table 3. The only relation of clinical parameters with 
MUC1 expression was the relation of a negative family history of breast cancer 
with MUC1 focal cytoplasmic expression (p=0.042). Screen-detected lesions and 
menopausal status were not associated with any type of MUC1 expression. 
MUC1 apical membrane expression was associated with low grade DCIS 
(European Pathologists Working Group [EPWG] classification [p=0.027] and Van 
Nuys classification [p=0.032]). MUC1 focal cytoplasmic expression was related 
with high grade according to the Van Nuys classification (p=0.006). MUC1 
diffuse cytoplasmic expression was associated with high grade according to the 
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MUC1 expression and biological markers 
The relation of well known biological markers with MUC1 expression is 
displayed in Table 4. MUC1 entire membrane expression was related with Her2/
neu negativity (p=0.042). MUC1 apical membrane staining was associated 
with Her2/neu negativity (p=0.014) and PR positivity (p=0.005). MUC1 focal 
cytoplasmic expression was associated with cyclin D1 positivity (p=0.042). 
Diffuse cytoplasmic staining was related with Her2/neu positivity (p=0.043) and 
with cyclin D1 positivity (p=0.002).
MUC1 expression and local recurrence
After performing the above mentioned analyses it was noticed that the 
four types of MUC1 expression could be broadly divided into two different 
types of expression. Entire- and apical membrane expression, that both had 
a pathological and biological less aggressive signature, were combined and 
classified as membane expression. Focal- and diffuse cytoplasmic expression, 
that both had a pathological and biological more aggressive signature, were 
also combined and classified as cytoplasmic expression. In order to evaluate 
the relation between these two types of MUC1 expression with local recurrence 
the dominant type of MUC1 expression in each tumor was classified as 
membrane or cytoplasmic expression. In the case of multiple expression 
patterns in one lesion, the dominant type of expression was defined by the 
largest percentage of cells that displayed this type of expression.  
Thirty-nine patients were treated with BCS. Due to small numbers patients 
that had been treated with and without radiotherapy were evaluated for local 
recurrence. The overall local recurrence rate in the study group was 7 cases 
(2 invasive carcinoma and 5 DCIS). In univariate analysis low grade (Hazard 
Ratio [HR] 0.1, 95% Confidence Interval [CI] 0.02-0.9, p=0.04) was related with 
local recurrence-free survival and MUC1 cytoplasmic expression (HR 8.1, 95%CI 
1.0-68.0, p=0.04) was associated with local recurrence (Log Rank 5.2, p=0.02; 
Figure 2). In multivariate analysis cytoplasmic MUC1 expression was the only 
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Discussion
Five predefined different types of MUC1 expression were studied in a series 
of pure DCIS cases arranged in a tissue microarray. MUC1 expression was 
observed in all DCIS lesions (n=73, 100%) and most cases displayed a variable 
expression pattern (78%). Four out of five different types of MUC1 expression 
previously noticed in invasive breast cancer were present in DCIS. Entire 
membrane expression was related with Her2/neu negativity (p=0.042). Apical 
membrane expression was associated with low grade (p=0.027 and p=0.032), 
Her2/Neu negativity (p=0.014) and PR positivity (p=0.005). Focal cytoplasmic 
expression was related with high grade (p=0.006) and diffuse cytoplasmic 
expression was associated with high grade (p=0.004), a large tumour size 
(p=0.046), cyclin D1 positivity (p=0.002) and Her2/Neu positivity (p=0.043). 
Inside-out staining was not observed in DCIS. These four types of MUC1 
expression can be divided into two types of expression in which the expression 
patterns with a pathological and biological similar signature are combined. 
MUC1 cytoplasmic expression is an independent predictor of local recurrence 
(HR 8.5, 95% CI 1.0-73.0, p=0.04).
Construction of TMA in invasive breast carcinoma is more successful than in 
DCIS because DCIS lesions are more difficult to target manually. The scattered 
distribution and the small size of the ducts with tumour make it more difficult 
to obtain representative tissue punches. In this study, the most representative 
H&E section of every DCIS lesion was selected and after delineation of the 
largest lesions on the section by a permanent marker, three punches per lesion 
were taken out of the corresponding paraffin block. This strategy proved to 
be successful in 80 (92%) out of 87 lesions. In another study by Jirström et 
al, the success rate of targeting DCIS lesions for TMA was much lower (52%) 
and the authors claim that part of this low success rate was due to extensive 
sectioning of all paraffin blocks prior to the TMA procedure.12
The MUC1 gene encodes a sialylated transmembrane glycoprotein with a 
large mucin-like domain consisting of 20-amino acid repeats which are rich in 
serines, threonines and prolines.13,14 After synthesis in the rough endoplasmatic 
reticulum, it is packaged in the Golgi apparatus and carried to the luminal 
domain of the cell membrane, where it exerts anti-adhesive and lubricant 
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membrane. During malignant transformation of breast carcinoma cells, MUC1 
expression may undergo changes that have morphological consequences.  
The evaluation of immunohistochemical staining of MUC1 in breast 
malignancies has been described in several reports. In invasive carcinoma 
cytoplasmic- and membrane staining have been reported16-19, whereas other 
studies report apical staining20-23 and staining of intracytoplasmic canaliculi24 
in addition to the former two types of staining. In the study by Hayes et al.22 
cytoplasmic staining is divided in cytoplasmic-vacuolar and cytoplasmic-
nonvacuolar expression. Many investigators also use the percentage of stained 
tumour cells18-20,25 and the intensity of staining as a quantification of MUC1 
expression.18,26 The expression of MUC1 in DCIS is less extensively evaluated 
than in invasive carcinoma, but apical- , membrane- and cytoplasmic staining 
have been reported.6,7 
In a review by Rahn et al.23 the overall percentage of MUC1 expression 
in invasive cancer was found to be increased in lower grade and estrogen 
receptor positive tumors. In that review high perentage of MUC1 expression 
was associated with a better prognosis, and cytoplasmic and circumferential 
membrane staining were associated with a worse prognosis. Subgroup 
analysis of MUC1 diffuse cytoplasmic expressing tumours in our invasive 
series also shows a relation with a worse prognosis whereas entire membrane 
staining, in that study, has no prognostic power (unpublished observations). 
A recent report by Rakha et al.20 investigated a large series of invasive breast 
carcinomas (n=1447) and found a positive relation of MUC1 expression with 
lower histological grade, smaller tumour size, ER expression and absence of 
both regional recurrence and distant metastasis. In that study, cytoplasmic 
and membranous expression of MUC1 were associated with poor outcome.20 
Cytoplasmic expression of MUC1 is positively correlated with Her2/neu 
overexpression and grade and cytoplasmic distribution is also inversely 
correlated with estrogen receptor status.15,26 In DCIS, cytoplasmic expression 
of MUC1 is associated with a high grade but it has also been reported that 
membrane staining is related with high grade if cytoplasmic expression is 
excluded.6,7 
In the evaluation of these reports, one should be aware of the fact that 
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repeat domain of MUC1 which is glycosylated to various degrees with 
different compositions of the carbohydrate side chains. As a consequence, 
immunohistochemical detection of MUC1 depends to a great extent on 
the sensitivity of a particular antibody to the degree and make-up of the 
glycosylation.8 For that reason we used an antibody which is almost insensitive 
to these factors.9
The patterns of MUC1 expression that have been predefined in our previous 
studies in a set of invasive ductal carcinomas of the breast were applied 
to DCIS in the present study.27 Because most DCIS lesions displayed a high 
overall percentage of MUC1 expression, we did not further evaluate the 
overall expression as a prognostic parameter. Entire membrane expression 
was related with Her2/neu negativity (p=0.042). Apical membrane expression 
was associated with low grade (p=0.027 and p-0.032), Her2/Neu negativity 
(0.014) and positive staining for PR (0.005). In our observations in invasive 
ductal carcinoma apical membrane expression was also related with lower 
pathological grade and PR expression but also with ER positivity (unpublished 
data). Focal cytoplasmic expression was related with high grade (p=0.004). 
Diffuse cytoplasmic expression was positively associated with grade (p=0.004) 
and Her2/neu overexpression (p=0.043) as is observed in invasive cancer.18,26 It 
can be concluded from these data that the classification for MUC1 expression 
is strongly related with tumour differentiation as shown by pathological 
characteristics and biological markers.
From the former observations two types of expression were identified; 
membrane expression has a pathological and biological less aggressive 
signature, whereas cytoplasmic expression has a more aggressive signature 
which is also demonstrated by the relation with local recurrence (HR 8.5, 95% 
CI 1.0-73.0, p=0.04). One might think that the fact that only half of the patients 
was treated with adjuvant radiotherapy has confounded the results of this 
outcome analysis. Due to small numbers patients treated with BCS with and 
without adjuvant radiotharpy were analysed together. However, we think that, 
in this study, the effect of radiotherapy can be disregarded because in the 
univariate analysis adjuvant radiotherapy was not significantly related to local 
recurrence (HR 1.5, 95% 0.3-8.4, p=0.63).
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overexpression of MUC1 is involved in modulating cell adhesion, in inducing 
invasive potential, and in affecting various signal transduction pathways.28 
Based on the first two of these features of MUC1 and on the relationship 
between clinico-pathological parameters and pattern of MUC1 expression, 
it is likely that MUC1 can play a decisive role in the transition from in 
situ to invasive ductal carcinoma. The absence of the inside-out staining 
pattern in DCIS as described here supports this notion, also because MUC1 
is expressed at the leading edge of tumor cells localized at the invasive 
front of adenocarcinomas.29 In contrast to DCIS which are almost exclusively 
MUC1 positive, a minority of invasive ductal carcinomas are MUC1 negative 
and appear to be a subgroup with a poor prognosis (unpublished data). This 
indicates that both aberrant MUC1 expression and absent MUC1 expression can 
favour more aggressive tumour progression, probably via different mechanisms 
comprising different factors involved in e.g. cell adhesion and invasion.
In summary, patterns of MUC1 expression were evaluated in invasive breast 
cancer and tested in a series of DCIS lesions. The expression on TMA shows 
that the different types of MUC1 staining, that are expressed in invasive 
breast cancer, are also present in DCIS, except for inside-out staining. Inside-
out expression is present in invasive breast carcinoma, but not all invasive 
carcinomas, and it was absent in DCIS lesions. This indicates that inside-out 
expression is a marker for invasive disease, possibly with a worse prognosis. 
Entire- and apical membrane staining and focal- and diffuse cytoplasmic 
staining were associated with pathological grade and biological markers, 
which suggests that the present classification of MUC1 expression patterns 
is an indicator of functional differentiation. A division of these four types of 
expression in membrane- and cytoplasmic expression is of clinical relevance 
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Table 5. Univariate analysis investigating the relation of pathological and 
biological characteristics with local recurrence in patients treated with 
breast conservation.
Pathological and  
biological features
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Table 6. Multivariate analysis investigating the relation of pathological and 
biological characteristics with local recurrence in patients treated with 
breast conservation.
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Abstract
Aims: MUC1 expression was classified according to five predefined 
expression patterns in invasive ductal breast carcinoma and related to clinico-
pathological parameters, co-expression of other biological markers and 
prognosis.
Methods and Results: Samples from 243 consecutive patients with 
primary ductal carcinomas were incorporated in tissue microarrays (TMAs). 
Slides were stained for MUC1, ER, PR, Her2/neu, p53, Cyclin D1. MUC1 apical 
membrane expression was associated with smaller tumours (p=0.001), lower 
tumour grades (p<0.001), ER positivity (p=0.049), PR positivity (p=0.003) and 
increased overall survival (OS, p=0,030). MUC1 diffuse cytoplasmic expression 
was associated with PR and Cyclin D1 positivity (p=0.018 and p=0.009), and 
increased relapse free survival (RFS, p=0.034). MUC1 inside-out expression 
was associated with ER positivity (p=0.026). Negativity for MUC1 was 
associated with ER negativity (p=0.004), PR negativity (p=0.001), Cyclin D1 
negativity (p=0.009). In stepwise multivariate analysis MUC1 negativity was an 
independent predictor of both RFS (HR 3.5, 95% CI 1.5-8.5, p=0.005) and OS (HR 
14.7, 95% CI 4.9-44.1, p<0.001). 
Conclusions: The expression pattern of MUC1 in invasive ductal breast 
carcinoma is related to tumour characteristics and clinical outcome. In 
addition, a MUC1 negative expression pattern is an independent risk factor for 
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Introduction
MUC1 (episialin, epithelial membrane antigen (EMA), CA15-3 antigen) is a 
highly O-glycosylated mucin-like transmembrane glycoprotein encoded by a 
gene on chromosome 1q21.1 This protein has a very large extracellular domain 
mainly consisting of 20 amino acid tandem repeats (TRs), a transmembrane 
domain, and a cytoplasmic tail.2-4
In most normal glandular epithelial cells, MUC1 is expressed on the apical 
surface5. In vitro and in vivo studies have described cell adhesion inhibition 
as well as increased metastatic and invasive potential of tumour cells by 
overexpression of MUC1.6-8 In MUC1 deficient mice primary breast tumours had 
a significantly lower growth rate.9 Overexpression of an underglycosylated form 
of MUC1 occurs in nearly all breast carcinomas.10-12
Using numerous different antibodies and scoring methods, many authors 
described correlations between MUC1 expression and ER status, grade of 
differentiation and prognosis.13-15 In contrast with the in vitro work, most of 
these studies show a better outcome for patients overexpressing MUC1. Four 
studies, however, found no relation between MUC1 expression and outcome.16-19 
These differences may be explained by the complex scoring system used, 
the different affinity of the applied antibodies for the glycosylated isoforms 
of MUC1, and the wide range of histopathological phenotypes of breast 
carcinomas with different clinical and prognostic implications.20 
Therefore, we used a monoclonal antibody directed at the protein backbone 
of MUC1 (mAb 214D4), which is relatively insensitive to the degree and make-
up of glycosylation of the molecule21, to study five patterns of MUC1 expression 
in primary ductal carcinomas which were predefined by two of the authors (CP 
and JP). To test the potential of this scoring method we applied it to a set of 
primary invasive ductal breast carcinomas not otherwise specified arranged in 
a tissue microarray (TMA) and related the MUC1 expression patterns to clinico-
pathological parameters, a series of well established biological markers, and 
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Materials and methods
Patients
243 consecutive patients treated for a primary operable invasive ductal 
carcinoma of the breast not otherwise specified at the University Medical 
Center Groningen between January 1996 and December 2001 were included 
in this study. Patient and tumour characteristics and data on follow-up were 
obtained retrospectively from hospital records and are summarized in table 
1. The median follow-up was 60.5 months (range 0.4 – 108.2). Follow-up was 
performed according the regional follow-up guidelines (http://www.ikcnet.nl/
page.php?id=97). During follow-up 12 patients developed a local recurrence 
after a median follow-up of 26.7 months. 33 patients developed distant 
metastasis after a median follow-up of 36.7 months. In total 41 patients 
presented with a relapse with a median relapse free survival (RFS) of 27.3 
months. 20 patients died due to breast cancer with a median overall survival 
(OS) of 34.1 months. 
Tissue microarray construction
From the patient’s tumour paraffin block, three 0.6 mm core samples of the 
most representative tumour area were included in a tissue microarray. The 
technique of tissue microarray production has been described and validated 
for breast carcinoma by others.22, 23 In brief, the most representative tumour 
area was marked on the original hematoxylin- and eosin (H&E) stained section. 
Using this section as an orientation, three 0.6 mm core punches were taken 
from the selected area in the donor blocks and mounted in a recipient block, 
using a manual tissue microarray device (Beecher Instruments, Silver Springs, 
MD, USA).
Immunohistochemistry
Immunohistochemistry for MUC1, ER, PR, Her2/neu, Cyclin D1 and p53 
was performed on these sections. The antibodies and antigen retrieval 
methods used are summarized in table 2. The immunostaining protocol 
was as follows: sections were deparafinized in pure xylene, rehydrated in 
decreasing concentrations of ethanol and washed in distilled water. Antigen 
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incubating in 3% perhydrol for 30 minutes. The primary antibody diluted in 
PBS containing 1% Bovine Serum Albumin was incubated for one hour, after 
which the secondary (1:100 diluted in PBS containing 1% BSA and 1% AB-
serum) and tertiary (1:100 diluted in PBS containing 1% BSA and 1% AB-serum) 
were incubated for 30 minutes each. Visualisation was performed using the 
diaminobenzidine tetrahydrochloride / peroxidase reaction. Counterstaining 
was performed using haematoxylin. Sections were dehydrated using rising 
concentrations of alcohol and were mounted. 
Evaluation of immunohistochemistry
Scoring of the stainings was performed by a well trained resident (BvdV). 
The scoring was randomly verified by an experienced pathologist (JW). ER, 
PR , p53 and Cyclin D1 were graded based on the percentage of tumour cells 
showing positive nuclear staining. ER, PR and Cyclin D1 were considered 
positive if nuclear staining was present in ≥10% of the cells, and p53 was 
considered positive in case of a substantial percentage of positively stained 
nuclei (>30%). Her-2/neu expression was graded as recommended by the 
manufacturerer’s scoring guidelines: 0: no staining at all or membrane staining 
in <10% of the tumour cells; 1+: a faint/barely perceptible partial membrane 
staining in >10% of the tumour cells; 2+: weak to moderate complete 
membrane staining in >10% of the tumour cells; 3+: strong complete membrane 
staining in >10%. Her-2/neu was considered positive if the score was 3+. MUC1 
was graded according the five expression patterns as depicted in figure 1. 
MUC1 expression was considered positive if there was staining in >10% of the 
tumour cells.
Data analysis
Data analysis was performed using the SPSS 12.0.1 statistical package (SPSS 
inc., Chicago, IL, USA). Chi-square tests were used to evaluate the associations 
of MUC1 expression with clinico-pathological parameters and biological 
markers. If applicable the Fisher Exact Test was used. Kaplan Meier (KM) 
curves were plotted and log-rank scores were calculated. P values of <0.05 were 
considered significant. After performing the analysis mentioned above the six 
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location: entire membrane, apical membrane and inside-out expression were 
classified as membrane expression; diffuse cytoplasmic and focal cytoplasmic 
were classified as cytoplasmic expression; tumours negative for MUC1 were 
classified as negative. These groups and other well established prognostic 
indicators were entered in an univariate Cox regression analysis to analyse 
the relationship with RFS and OS. Variables from the univariate analysis with 
a p value of <0.05 were then entered in a stepwise multivariate Cox regression 
analysis to investigate the relationship with RFS and OS.
Results
Tissue microarray and immunohistochemistry
Of the 243 cases included, the tissue cores of 237 cases were adequately 
represented in the TMA. Immunohistochemistry could be evaluated in all cases 
(100%, n=237) for MUC1, p53 and Cyclin D1, in 235 cases (99.2%) for Her2/neu, 
in 232 cases (97.9%) for ER and in 230 cases (97.0%) for PR.
In the assessable cases, MUC1 was expressed in 221 cases (93.2%) showing 
either a single or a combination of expression patterns. 16 cases (6.8%) did 
not show any expression of MUC1. Entire membrane expression was seen 
in 48 cases (20.3%). 64 cases (27.0%) showed apical expression. In 21 cases 
(8.9%) focal cytoplasmic expression was seen. The most common expression 
was diffuse cytoplasmic (73.0%, n=173). Inside-out expression was seen in 23 
cases (9.7%). 117 cases (49.4%) showed a single expression pattern. The most 
common single expression pattern was diffuse cytoplasmic expression (70.1%, 
n=82). 100 cases (42.2%) showed a combination of two patterns and 4 cases 
(1.7%) showed a combination of three expression patterns. The most common 
combination of expression patterns was apical and diffuse cytoplasmic 
expression (40.3%, n=42). 
MUC1 expression and clinico-pathological parameters
The relationship between MUC1 expression pattern and clinico-pathological 
parameters is shown in table 3. MUC1 apical expression is associated with 
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MUC1 expression and biological markers
Table 4 shows the relationship between MUC1 expression and other 
biological markers. 
For MUC1 apical expression significant associations with ER (p=0,049) and PR 
(p=0,003) expression were found. Diffuse cytoplasmic MUC1 expression showed 
associations with PR (p=0.018) and Cyclin D1 (p=0.009). For MUC1 inside-out 
expession there was a signifcant association with ER (p=0.026). Negativity for 
MUC1 expression was associated with ER (p=0.004), PR (p=0.001) and Cyclin D1 
(p=0.009).
MUC1 expression and clinical outcome
Kaplan Meier survival curves showed no significant correlation between 
MUC1 expression at the entire membrane and OS or RFS. Patients with tumours 
that had apical MUC-1 expression displayed a better OS (p=0.030; fig. 2b). 
No relationship between focal cytoplasmic MUC1 expression and survival 
was found. Patients with tumours that showed diffuse cytoplasmic MUC1 
expression had a better RFS than patients with tumours that did not show 
diffuse cytoplasmic MUC1 expression (p=0.034; fig. 2a). For MUC1 inside-out 
expression, no correlation with survival was found. MUC1 negativity was 
significantly associated with worse RFS (p= <0.001) and OS (p= <0.001; fig. 2c, 
fig. 2d).
Analysis of combinations of MUC1 expression patterns, clinico-pathological 
parameters, biological markers, and clinical outcome
In order to increase the power of an outcome analysis the expression 
patterns were broadly divided into three patterns on the basis of location of 
MUC1 expression. Apical membrane expression and inside-out expression, 
that both had a biological less aggressive signature, were combined with 
entire membrane expression and classified as membrane expression. Diffuse 
cytoplasmic expression was combined with focal cytoplasmic expression 
and classified as cytoplasmic expression. Tumours that did not show MUC1 
expression were classified as MUC1 negative. In order to evaluate the 
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the dominant type of MUC1 expression in each tumour was classified as 
membrane or cytoplasmic expression, or as MUC1 negative. In the case of 
multiple expression patterns in one lesion, the dominant type of expression 
was defined by the largest percentage of cells that displayed this type of 
expression.
The results from univariate Cox regression analysis for RFS are shown 
in table 5. Significant relations were found for tumour size (HR 2.2, 95% CI 
1.1-4.5, p=0.03 for tumours between 2.0 and 5.0 cm; HR 3.8, 95% CI 1.4-10.2, 
p=0.009 for tumours >5 cm), tumour grade (HR 2.3, 95% CI 1.2-4.2, p=0.009), 
MUC1 expression (HR 3.4, 95% CI 1.5-8.1, p=0.005 for MUC1 negativity), Her2/
neu expression (HR 2.8, 95% CI 1.1-7.1, p=0.03), ER expression (HR 0.5, 95% CI 
0.3-1.0, p=0.05), PR expression (HR 0.4, 95% CI 0.2-0.7, p<0.01) and relapse free 
survival.
In table 6 the results from univariate Cox regression analysis for OS are 
shown. Significant results were found for tumour size (HR 6.6, 95% CI 1.6-26.4, 
p=0.008 for tumours >5 cm), tumour grade (HR 3.6, 95% CI 1.5-8.7, p=0.005), 
axillary lymph node status (HR 3.0, 95% CI 1.1-7.8, p=0.03), reception of 
adjuvant chemotherapy (HR 3.2, 95% CI 1.1-8.8, p=0.02), MUC1 expression (HR 
6.0, 95% CI 2.2-16.7, p=0.001), Her2/neu expression (HR 6.3, 95% CI 2.2-17.5, 
p<0.001), ER expression (HR 0.3, 95% CI 0.1-0.8, p=0.02), PR expression (HR 0.4, 
95% CI 0.2-1.0, p=0.05) and overall survival.
The results from the stepwise multivariate analysis for RFS are shown in 
table 7. MUC1 expression (HR 4.6, 95% CI 1.5-8.5, p=0.005 for MUC1 negativity) 
and PR expression (HR 0.4, 95% CI 0.2-0.8, p=0.09) were significant independent 
predictors of relapse free survival.
In table 8 the results from multivariate analysis for OS are shown. Axillary 
lymph node status (HR 4.7, 95% CI 1.7-13.0, p=0.003), MUC1 expression (HR 
14.7, 95% CI 4.9-44.1, p<0.001 for MUC1 negativity) and Her2/neu expression (HR 
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Discussion
This study investigated the relationship between MUC1 expression patterns 
in invasive ductal carcinomas of the breast not otherwise specified, tumour 
characteristics, expression of a series of well established tumour markers, and 
clinical outcome. To avoid ambiguous results due to the heterogeneity of breast 
cancer, we focused on this by far most common type of breast cancer. 
We found expression in 93.2% percent of the cases. MUC1 apical expression 
was significantly associated with smaller tumours, lower tumour grades, ER 
positivity and PR positivity. MUC1 diffuse cytoplasmic expression showed 
a significant association with PR and Cyclin D1 positivity. MUC1 inside-
out expression was associated with ER positivity. Negativity for MUC1 was 
significantly associated with ER negativity, PR negativity and Cyclin D1 
negativity. Patients with apical MUC1 expressing tumours and patients with 
diffuse cytoplasmic MUC1 expressing tumours displayed a significantly 
increased RFS. Patients with tumours negative for MUC1 showed a significantly 
decreased RFS and OS in both univariate and multivariate analysis.
Before discussing the associations found for the different expression 
patterns of MUC1 in more detail, it is important to discuss the antibodies used 
to detect MUC1 in various studies. Almost all anti-MUC1 antibodies used are 
directed against the O-glycosylated extracellular MUC1 tandem repeat domain.13 
However, the degree and make-up of glycosylation may vary extensively 
among MUC1-positive adenocarcinomas24, 25 and the affinity for MUC1 of the 
vast majority of these antibodies depends on the extent and composition of 
glycosylation26, 27. As a consequence, the variety of anti-MUC1 antibodies used 
to determine MUC1 expression in breast carcinomas may explain at least part 
of the discrepancies between various studies as discussed below.
Detecting almost all glycosylated MUC1 isoforms is important to study its 
significance for tumour progression, relationship to other tumour progression 
markers and to clinical outcome. Some well established functions of MUC1, 
e.g. the inhibition of cell-cell and cell-extracellular matrix adhesion, are only 
to a minor extent dependent of the MUC1 glycosylation status.7, 28 For that 
reason we used mAb 214D4, a monoclonal antibody which is also directed to 
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almost independent of the glycosylation status.21
In normal glandular epithelium, MUC1 is expressed at the apical surface.5 
For that reason apical expression in breast carcinomas (designated ‘pattern 
B’; fig.1) indicates normal routing of MUC1 molecules and as a consequence 
relatively intact glandular differentiation. Indeed, in our series, apical MUC1 
expression is associated with many indicators of good prognosis and a better 
OS. The association with lower tumour grades11, 13, 15, 29, ER15, 29 and PR29 positivity 
and the absence of distant metastasis15 has been described. Some authors 
found an increased rate of axillary lymph node negativity15 and longer RFS for 
patients with tumours expressing MUC1 apically.15, 30 In our data these findings 
could not be confirmed. Study size, follow-up and patients included in these 
studies might account for this difference, e.g. the study by Hayes et al only 
included node positive patients. In accordance with our series an increase 
in OS of patients with tumours expressing MUC1 apically has been reported 
elsewhere.15, 31 One relatively small study did not find an association between 
apical expression and clinico-pathological variables.32 
Entire membrane MUC1 expression (designated ‘pattern A’; fig. 1) is more 
often seen in mucinous carcinomas than in ductal carcinomas of no special 
type.12 Although this expression pattern appears to be the effect of misrouting 
in the MUC1 pathway, no unambiguous results on the role of MUC1 expression 
on the entire membrane in breast cancer have been described. Where Parham 
et al showed that high entire membrane expression of MUC1 associates with 
low tumour grades17, Rahn et al showed the contrary.13 The former study 
also found an association with positive lymph node status. In this study 
no significant associations between MUC1 entire membrane expression and 
clinico-pathological parameters were found. Entire membrane MUC1 expression 
did not associate with clinico-pathological characteristics and outcome in these 
series. Two other studies that looked at a relation between expression of MUC1 
on the entire membrane and outcome also did not find such a relation.11, 17 
By combining entire membrane and cytoplasmic MUC1 expression Rakha et al 
were able to show a significant decrease in OS and RFS in this group.15 We did 
not perform such a subgroup analysis. 
Inside-out expression (designated ‘pattern E’; fig. 1) for MUC1 was present 
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authors (CP, JP) before.33 This pattern is specific for invasive micropapillary 
carcinoma, a subtype of ductal breast carcinoma with a high potential to 
metastasize to the axillary lymph nodes.34 We did not find such a relation 
however, nor did we find an association between ‘inside out’ expression and 
outcome. The small number of cases in these series might account for this.
Diffuse cytoplasmic expression of MUC1 was associated with good prognosis 
in these series. Previous reports have linked cytoplasmic expression of 
MUC1 to ER negativity15, high Her2/neu expression35, decreased RFS11, 15, 31 and 
decreased OS.15, 31 The study by Lundy et al, found that MUC1 cytoplasmic 
expression was related to ER positivity and lower tumour grades.32 In this study 
a positive relation of MUC1 diffuse cytoplasmic expression with PR and Cyclin 
D1 positivity was found which might be explained by the common combination 
of apical and diffuse cytoplasmic expression in these series. Results from the 
subgroup analysis of combined apical and diffuse cytoplasmic MUC1 expression 
versus strictly cytoplasmic MUC1 expression show that tumours with diffuse 
cytoplasmic MUC1 expression have a clinico-pathological profile that is 
usually associated with worse outcome, but that when there is a combination 
with apical MUC1 expression (so a part of the MUC1 is routed correctly) this 
negative effect disappears. 
Focal cytoplasmic expression of MUC1 has been described in lobular 
carcinomas.12, 36 To our knowledge it has not been described in ductal 
carcinomas before. We did not find any relationship between focal cytoplasmic 
expression (designated ‘pattern C’) and any of the investigated variables.
We observed that tumours negative for MUC1 had a very poor outcome 
with respect to RFS and OS (figure 2 C and 2 D). In addition, absence of 
MUC1 expression was associated with absence of ER, PR and Cyclin D1. These 
findings support the observation by Luna-More et al, that tumours negative 
for MUC1 have high tumour grades, are ER and PR negative, and are more 
frequently associated with positive axillary lymph nodes.29 Other studies have 
related low or negative MUC1 expression to higher tumour grades13 and poor 
prognosis.37 In inflammatory breast carcinoma patients with MUC1 negative 
tumours had a significantly shorter OS.38 Remarkably, our MUC1-negative group 
of breast carcinomas appears to be a subgroup with poor prognosis that can 
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survival MUC1 negativity was the strongest independent predictor (see tables 7 
and 8). 
We also performed a study with MUC1 expression in ductal carcinoma in 
situ (unpublished results). When comparing the results of that study with 
the current study some interesting differences can be noted. The inside-out 
expression pattern is exclusively seen in invasive ductal carcinomas and not 
in ductal carcinoma in situ (DCIS). Also in DCIS no MUC1 negative tumours 
were found. As mentioned before the inside-out expression pattern is specific 
for invasive micropapillary carcinoma. MUC1 negative tumours are a subgroup 
of tumours that is non-luminal, non mucin producing. These tumours are 
probably fast growing and aggressive and may not have a stage of non-
invasive growth that can be diagnosed because of early invasion. Loss of MUC1 
might play a role in this process of early invasiveness. Remarkably, this seems 
to be in contrast with in vitro and in vivo data which show that membranous 
MUC1 overexpression favours adhesion modulation, invasive potential, and 
metastatic capacity of tumour cells.6-9 These effects are very likely due to steric 
hindrance of adhesion molecules by the high density of large and elongated 
extracellular MUC1 domains at the cell surface.7 Without doubt, there are more 
mechanisms available for acquiring invasive potential, e.g. inactivation of 
the E-cadherin/β-catenin complex as in invasive lobular breast carcinoma. To 
investigate a potential relationship between MUC1 and E-cadherin expression, 
we performed immunohistochemistry for E-cadherin and β-catenin. However, 
both stainings were too heterogeneous and irreproducible for a reliable 
semiquantitative analysis (data not shown).
We realize that in this outcome study patients have been treated in a very 
heterogeneous manner (radiotherapy, chemotherapy and hormonal therapy), 
and that this may have confounded the results somewhat. However, in 
univariate analysis radiotherapy is not an predictor for both OS and RFS. In 
multivariate analysis MUC1 negativity remains an independent predictor of 
RFS and OS suggesting an effect independent from adjuvant chemotherapy. 
Also one could argue that the great amount of analysis undertaken in this 
study has led to significant results. However, in this study we focused on the 
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biomarkers selected based on their established role in the tumour biology of 
carcinomas and in breast carcinoma in particular. Therefore the authors think 
the conclusions of this study are still valid.
In conclusion, this study has shown that determination of the MUC1 
expression pattern may play a role in the classification and prognosis 
prediction of breast cancer. Normal apical expression of MUC1 was associated 
with a good prognosis whereas cytoplasmic MUC1 expression was associated 
with worse prognostic tumour characteristics. A MUC1 negative expression 
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Table 1. Patient and tumour characteristics.
n %
Age at diagnosis



































Pathological tumour size (mm)









































n: number of cases; %: percentage; BCT: breast conserving therapy; mm: millimeter; T1: tumour 
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Table 5. Univariate analysis investigating the relation of pathological and 
biological characteristics with relapse free survival.
Pathological and 
biological features
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Table 6. Univariate analysis investigating the relation of pathological and 
biological characteristics with overall survival.
Pathological and 
biological features
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Table 7. Stepwise multivariate analysis investigating the relation of 
pathological and biological characteristics with relapse free survival.


















Table 8. Stepwise multivariate analysis investigating the relation of 
pathological and biological characteristics with overall survival.
Characteristics HR 95% CI p-value
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Figure 2. Correlation between the MUC1 expression pattern and relapse free (A 
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Abstract
Background: The incidence of ductal carcinoma in situ (DCIS) has risen 
dramatically with the introduction of screening mammography. The aim was 
to evaluate differences in pathological and biological characteristics between 
patients with screen-detected and interval DCIS. 
Methods: From January 1992 to December 2001, 128 consecutive patients 
had been treated for pure DCIS at our institute. From these 128,102 had 
been attending the Dutch breast cancer screening programme. Sufficient 
paraffin embedded tissue was available in 74 out of the 102 cases to evaluate 
biological marker expression (Her2/neu, ER, PR, p53 and cyclin D1) on tissue 
microarrays (TMA-group). Differences in clinico-pathological characteristics 
and marker expression between screen-detected and interval patients were 
evaluated. Screen-detected DCIS was classified as DCIS detected by screening 
mammography, when the two-year earlier examination failed to reveal an 
abnormality. Interval patients were classified as patients with DCIS detected 
within the two-year interval between two subsequent screening rounds.
Results: Screen-detected DCIS was related with linear branching and coarse 
granular microcalcifications on mammography (p<0.001) and with high grade 
according to the Van Nuys classification (p=0.025). In univariate analysis 
screen-detected DCIS was related with Her2/neu overexpression (Odds Ratio 
[OR]=6.5; 95%CI 1.3-31.0; p=0.020) and interval DCIS was associated with low 
grade (Van Nuys, OR=7.3; 95% CI 1.6-33.3; p=0.010) and PR positivity (OR=0.3; 
95%CI 0.1-1.0; p=0.042). The multivariate analysis displayed an independent 
relation of Her2/neu overexpression with screen-detected DCIS (OR=12.8; 95%CI 
1.6-104.0; p=0.018). 
Conclusion: These findings suggest that screen-detected DCIS is 
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Introduction
With the introduction of widespread screening mammography, the incidence 
rates of ductal carcinoma in situ (DCIS) have risen dramatically in Western 
Europe and North America.1-3 DCIS now accounts for nearly 20% of all screen-
detected breast malignancies.4
As a consequence, treating physicians are confronted with a cumulative 
caseload because it is not known how many women with screen-detected 
DCIS will develop an invasive carcinoma in their lifetimes. The proportion of 
untreated cases of DCIS that would progress to invasive malignancy has been 
difficult to evaluate, because DCIS is usually excised when detected. Because 
DCIS is a non-obligatory precursor to invasive carcinoma, and, therefore, has 
a relatively benign nature, screen-detected DCIS has been argued to represent 
an overdiagnosis.5.,6 This argument is supported by autopsy studies in which 
the median prevalence of DCIS was 8.9% suggesting some cases do not 
progress to clinically significant lesions in a patient’s lifetime.7 On the contrary, 
patients with DCIS treated with biopsy alone in the premammography era had 
a higher rate of subsequent occurrences (14-50%) of invasive breast cancer 
than expected.8,9 Large clinical trials, in which patients had been treated with 
lumpectomy alone, have also indicated that DCIS can recur as invasive ductal 
carcinoma.10,11 
Screen-detected DCIS is more often presented as linear branching 
microcalcifications on mammography than symptomatic DCIS.12 The screen-
detected group in the previously mentioned study had a larger proportion 
of patients with comedocarcinoma. Therefore, it was suggested that linear 
branching microcalcifications were related with a more aggressive type of 
DCIS.12 This is confirmed in other reports which have indicated that linear 
branching microcalcifications on mammography are associated with high 
grade.13,14
We believe that screen-detected DCIS is more often associated with 
suspicious microcalcifications representing high grade DCIS which has 
been detected before it has had the chance to progress to invasive cancer. 
Therefore, it is hypothesized that screen-detected DCIS is biologically more 
aggressive than interval DCIS. In order to compare screen-detected DCIS with 
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characteristics of both groups were evaluated for differences. Screen-detected 
DCIS was classified as DCIS detected by screening mammography, when the 
two-year earlier examination failed to reveal an abnormality. Interval DCIS 
was classified as DCIS detected within the two-year interval between two 
subsequent screening rounds, when the earlier examination failed to reveal an 
abnormality. Age, tumour size, and pathological grade were studied for their 
known relation with local recurrence. Finally, the expression of established 
prognostic biomarkers in breast cancer was studied by immunohistochemistry 




The Dutch screening programme for breast cancer has been gradually 
implemented in the North Netherlands since 1991. It offered biennial 
mammography to women aged 50-69 years and since 1999 women aged 70-74 
have also been included. Women received mammography in the cranio-caudal 
and medio-latero-oblique direction for each breast. Two radiologists evaluated 
the mammograms by a double, independent reading. 
In the period from January 1992 to December 2001 128 consecutive patients 
had been treated for pure DCIS at our institution. To identify patients for 
inclusion in the study all women who had actually attended the screening 
programme at least two subsequent rounds with a two-year interval at the 
time of diagnosis were considered as attenders. Patients that had skipped 
one or more screening rounds previous to the diagnosis and patients who had 
not been attending the programme at all were considered non-attenders. In 
order to obtain this information patients records were checked and if there 
was no information regarding the participation of the screening programme 
at the time of diagnosis the general practioner was consulted. Out of the 128 
consecutive patients 102 attenders and 26 non-attenders could be identified. 
For immunohistochemistry patients were selected on the availability of 
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74 out of the 102 attenders remained, respectively, for evaluation of Her2/neu 
overexpression, oestrogen receptor (ER) expression, progesterone receptor (PR) 
expression, p53 expression and cyclin D1 expression using tissue microarray 
analysis as part of a project protocol that had been approved by the medical 
ethics committee. The patients in the study-group (n=74) were divided into two 
groups. Patients with DCIS that had been detected by screening mammography 
were classified as screen-detected patients, when the two-year earlier 
examination failed to reveal an abnormality (n=54). Patients with DCIS that had 
been detected within the two-year interval between two subsequent screening 
rounds were classified as interval patients, when the earlier examination failed 
to reveal an abnormality (n=20).
Mammography and pathological assessment
Mammographic and pathological characteristics were derived from 
mammography and pathological reports, respectively. Data were delivered 
and evaluated anonymously. If data were missing, mammography and 
pathological slides were re-evaluated. Mammographic appearances were 
scored as microcalcifications, a mass, a combination of the two, or as occult. 
Microcalcifications were scored as fine granular, coarse granular or as linear 
branching. Pathological size had been estimated and the grade had been 
scored according to the European Pathologists Working Group (EPWG15) and 
according to the Van Nuys classification.16
Tissue microarray construction
Slides from all blocks were evaluated for representative areas with DCIS 
and tissue microarrays were prepared as described earlier17. In brief, the 
most representative area of DCIS was marked on the original haematoxylin 
and eosin (H&E) stained section. With this marked section as an orientation, 
three 0.6 mm punches were taken from the selected area in the donor blocks 
and mounted in a recipient block containing approximately 110 biopsies, 
using a manual tissue microarray device (Beecher Instruments, Silver Springs, 
MD, USA). The presence of DCIS in the arrayed samples was verified on 
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Immunohistochemistry
For immunohistochemistry, 3 μm sections of the paraffin embedded 
tissue arrays were deparaffinised in 2 changes of xylene for 5 minutes each 
and gradually rehydrated through changes of graded ethanol from 100% to 
distilled water. Antigen retrieval methods and antibodies are summarized in 
Table 1. The endogenous peroxidase reaction was blocked by incubating the 
sections in 3% perhydrol for 30 minutes. Primary antibodies were diluted in 
PBS contaning 1% Bovine Serum Albumin and incubated at room temperature 
for 1 hour. Samples were then washed in PBS and incubated with secondary 
and tertiary antibodies. For visualization of the antibody-antigen complex, the 
diaminobenzidine tetrahydrochloride/ peroxidase reaction was used. After a 
final wash with distilled water, sections were counterstained with hematoxylin. 
Sections were dehydrated through rising concentrations of ethanol and 
mounted. Immunohistochemistry was successful in 81/87 cases for Her2/neu 
staining, 73/87 cases for ER staining, 71/87 for PR and cyclin D1 staining and 
70/87 for p53 staining.
Evaluation of immunohistochemical staining
All slides stained for molecular markers were read by two authors (MdR and 
BvdV). The slides were randomly reviewed by a third author (JW) and in case 
of disagreement between the other two authors. ER, PR and p53 were graded 
based on the percentage of cells showing positive nuclear staining in the ducts 
with DCIS. ER and PR were considered positive if nuclear staining was present 
in ≥10% of the cases, and p53 was considered positive in case of a substantial 
percentage of positively stained nuclei (>30%). Her2/neu expression was graded 
as recommended by the HercepTestTM scoring guidelines: 0: no staining at all 
or membrane staining in <10% of tumour cells; 1+: a faint/barely perceptible 
partial membrane staining in >10% of the tumour cells; 2+: weak to moderate 
complete membrane staining in >10% of tumour cells; 3+: strong complete 
membrane staining in >10%. Her-2/neu was considered to be overexpressed if 
the score was 3+. Cyclin D1 expression was scored using a semiquantitative 
system as described by Vos et al.18 This system was based on the staining 
intensity scored as 0 (none), 1 (weak), 2 (moderate), and 3 (strong), and the 
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50%), 3 (50-75%), and 4 (>75%). The cyclin D1 staining score was calculated as 
the sum of the intensity and the percentage of positive tumour cells.
Statistical analysis
Differences in clinico-pathological characteristics between screen-detected 
and interval patients with DCIS in the study-group, and between the study-
group and the exluded group of patients were analysed by chi-square analysis. 
Differences in clinico-pathological and biological characteristics between the 
study-group and the non-attenders were also analysed by chi-square analysis. 
Differences in age were tested by using the Mann-Whitney U test. Univariate 
analyses, investigating differences in pathological and biological features, 
was performed by logistic regression, using screen-detected as a dependent 
variable. Multivariate analyses were performed with a logistic-regression 
model. The elimination of variables in a stepwise manner identified the 
statistically significant pathological and biological parameters. A p value of ≤ 
0.050 was considered as significant. All calculations were performed with SPSS 
12.01 (SPSS inc., Chicago, IL, USA).
Results
Table 2 shows the clinico-pathological characteristics of the patients in 
the study group (n=74). Screen-detected DCIS was less often symptomatic 
than interval DCIS (p<0.001). Five patients (25%) in the interval group had 
no objective signs on presentation; all patients had felt a lump in the 
breast that could not be verified on clinical examination. On mammography 
microcalcifications were more often seen in screen-detected DCIS (p=0.002). 
Screen-detected DCIS was more often presented as linear branching- (44.9%) 
and coarse granular (55.9%) microcalcifications than interval DCIS (p<0.001). 
High grade (Van Nuys, 53.1%, p=0.025) was also more often observed in screen-
detected DCIS.
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(n=74) and the group of patients that had been exluded (n=28) because of 
insufficient paraffin embedded tissue are outlined in table 3. There was no 
marked difference in age, microcalcifications, tumour size and pathological 
grade according to the EPWG classification between both groups. The excluded 
group of patients represented a relatively large proportion of low grade 
according to the Van Nuys classification (p<0.001) in comparison with the TMA-
group.
Differences in clinico-pathological and biological characteristics between the 
study-group and the non-attenders (n=13) are summarized in table 4. Non-
attenders were younger than the patients in the study group (55.9 years versus 
59.6 years; p=0.042).
In Table 5 the relation between pathological characteristics, biological marker 
expression and mode of detection in the study-group is displayed. Univariate 
logistic regression analysis indicated that in screen-detected DCIS Her2/neu is 
more often overexpressed (Odds Ratio [OR]=6.5; 95% Confidence Interval [CI] 
1.3-31.0; p=0.020). Interval DCIS is more frequently positive for PR staining 
(OR=0.3; 95% CI 0.1-1.0; p=0.042) and is related to low pathological grade 
according to the Van Nuys classification (OR=7.3; 95% CI 1.6-33.3; p=0.010). In 
multivariate logistic regression, including pathological grade according to the 
EPWG and Van Nuys classification, Her2/neu overexpression and PR expression 
in the model, Her2/neu overexpression was the only independent indicator for 
screen-detected DCIS (OR=12.8; 95% CI 1.6-104.0; p=0.018).
Discussion
Approximately 1 in every 1300 screening mammography examinations 
leads to a diagnosis of DCIS.4 Data from a large trial and service screening 
programmes in the UK, the Netherlands, Australia and the USA have 
demonstrated that a woman attending prevalence screen has a 19 times 
greater chance of having a progressive DCIS or an invasive tumour diagnosed 
than of having a non-progressive DCIS diagnosed.19 It is questioned what to 
do with the high detection rate of screen-detected DCIS. It was hypothesized 
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because suspicious microcalcifications, detected by the screening programme, 
will probably more frequently represent high grade DCIS. Therefore screen-
detected DCIS was characterized pathologically and biologically in order to 
determine whether screen-detected DCIS differed from interval DCIS. The results 
of this study indicate that screen-detected DCIS is pathologically (OR=7.3; 95% 
CI 1.6-33.3; p=0.010) and biologically (OR=12.8; 95%CI 1.6-104.0; p=0.018) more 
aggressive than interval DCIS. Indeed screen-detected DCIS was related with 
more suspicious microcalcifications (p<0.001). DCIS detected by a prevalence 
screen was pathologically and biologically comparable to DCIS detected in later 
rounds (data not shown) suggesting prevalence and incident cases to be both 
of clinical relevance. 
The relative incidence of high grade DCIS in our series of screen-detected 
patients was 53% which is comparable to the incidence of high grade in a 
screening population from the Netherlands Cancer Institute (47%).21 Much data 
point out that poorly differentiated or high grade DCIS lesions have a greater 
potential to progress to invasive disease than low grade DCIS.20 High grade is 
also an independent risk factor of local recurrence after lumpectomy for DCIS 
and approximately 50% of these recurrences are invasive cancers.22,23 There are 
no studies available comparing screen-detected with interval DCIS in a group 
of patients that had all been attending the screening programme. Reports 
on screen-detected DCIS regarding histo-pathological grade vary markedly 
describing a higher incidence of low grade24, no difference25, or a higher 
incidence of high grade12,26,27 in screen-detected DCIS. In these reports screen-
detected DCIS is compared to symptomatic DCIS or to DCIS detected in a period 
before the screening programme was introduced. In the present study a higher 
incidence of high grade lesions, which were classified according Van Nuys 
(OR=7.3; 95% CI 1.6-33.3; p=0.010) classification, was found in screen-detected 
DCIS, indicating a higher malignant potential in screen-detected DCIS. These 
results are consistent with the results from the studies of Evans et al.26 and 
Kessar et al.27 
DCIS lesions from patients in the study group were compared to DCIS lesions 
from patients who had not attended the screening programme (table 4). Out 
of the 26 non-attenders there were only 13 patients from which sufficient 
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were no differences in pathological and biological characteristics between 
the two groups. The difference in age could be explained by the fact that the 
non-attenders-group also contained patients under 50-years of age. From 
these analyses it seems that DCIS in non-attenders is not pathologically 
and biologically more aggressive than DCIS in attenders of the screening 
programme. However, because of the very small number of patients in the 
non-attenders group no hard conclusions can be drawn.
Her2/neu overexpression has been found to correlate with various 
pathologic and biological factors believed to be associated with more 
aggressive behaviour; high grade, presence of necrosis, ER- and PR-negativity 
and overexpression of Ki-67 (indicating an increased proliferation rate) are 
features that are strongly related with Her-2/neu overexpression.28-30 The report 
of Walker et al.24 displayed a Her-2/neu expression of 59% in symptomatic DCIS 
and of 42% in mammographically detected DCIS. Another study by Idvall et 
al.25 reported no difference in Her-2/neu expression between DCIS before and 
after introduction of mammographic screening. In this present study Her2/neu 
overexpression was the only independent feature to be related with screen-
detected DCIS in multivariate analysis (OR=12.8; 95%CI 1.6-104.0; p=0.018) 
which indicates a more aggressive profile of screen-detected DCIS when 
compared to interval DCIS. 
Although the statistical methods used were univariate and multivariate 
analysis, the numbers in both groups are small, which explains the broad 
95% CI. The small numbers are due to the selection of patients in this study 
for study period, attendance of screening rounds and availability of sufficient 
paraffin embedded tissue. Clearly further studies with larger populations are 
needed to elucidate the relative significance of the Her2/neu overexpression 
in women with screen-detected DCIS. Although 28 out of 102 patients were 
excluded because of lack of sufficient paraffin embedded tissue, there is no 
reason to assume that this exclusion results in a significant selection bias. 
Apart from pathological grade according to Van Nuys, there were no differences 
in clinico-pathological characteristics between the study-group and the group 
of excluded patients. The group of excluded patients displayed a relatively 
large amount of low grade DCIS according to Van Nuys (53.6%, p<0.001), 
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If all patients would have been included the relation of pathological grade 
and probably Her2/neu expression with screen-detected patients would be 
even more significant. The inclusion of patients that actually took part in the 
screening programme was necessary to analyze differences between screen-
detected- and interval DCIS, which, to our knowledge, has not been performed 
previously. 
Expression of ER, p53 and cyclin D1 was not related to screen-detected or 
interval DCIS. There was, however, a relation between screen-detected DCIS 
and PR negativity in univariate analysis (OR=0.288; 95%CI 0.087-0.957; p=0.042). 
Other studies could not demonstrate a relation of screen-detected DCIS with 
the expression of the above mentioned markers.12,24,25 In a review by Boland 
et al.31 ER and PR positivity are related to low grade DCIS, whereas p53 and 
cyclin D1 expression are associated with high grade. The fact that screen-
detected DCIS is associated with PR-negativity provides indirect evidence for 
the presence of a more aggressive tumour biology. Obviously PR expression is 
related to Her2/neu expression, because PR expression was not significant in 
multivariate analysis. 
Ultimately, the question is how we should interpret these findings. The 
authors think the results from this study represent no evidence to alter patient 
management and screening recommendations. Instead, they should rather 
be regarded as support of current clinical practice in DCIS of the breast. They 
confirm that every DCIS should be treated until we are able to identify DCIS 
which will progress to invasive cancer if left untreated is.
In conclusion, since the advent of screening, the increased incidence of 
DCIS has raised concerns about the possibility of overdiagnosis of DCIS. This 
study has shown that screen-detected DCIS has a more aggressive tumour 
profile than interval DCIS. Therefore, screen-detected DCIS should not be 
regarded as an overdiagnosis per se and every woman diagnosed with DCIS 
by mammographic screening should be treated properly according to existing 
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Table 2. Clinico-pathological characteristics of the patients in the study-








Age (mean) 58.9 60.7 0.187¶
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Table 3. Comparison of clinico-pathological characteristics between the 
study-group and the group of patients that were excluded because of 
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Table 4. Differences in clinico-pathological and biological characteristics 
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Table 5. Univariate analysis of pathological and biological characteristics in 
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Abstract
There is debate whether interval carcinomas differ from screen detected 
tumours biologically. In this study clinico-pathological parameters and the 
expression of well validated biological markers were compared between ‘true’ 
interval carcinomas and screen detected- / missed carcinomas hypothesizing 
that ‘true’ interval carcinomas show a more aggressive biological behaviour. 
The study group consisted of 92 consecutive postmenopausal women attending 
the breast screening programme and presenting with an invasive ductal 
carcinoma. All screening mammograms were re-reviewed. 16 patients had a 
‘true’ interval carcinoma. 7 carcinomas were missed at screening, but detected 
upon re-reviewing of the screening mammogram. Radiological characteristics 
were assessed from diagnostic mammograms. Data on patient- and tumour 
characteristics and follow-up data were recorded from hospital records. Median 
follow-up was 61 months. Immunohistochemistry for ER, PR, Her2/neu and p53 
was performed on TMA sections. Univariate and multivariate logistic regression 
analyses were performed. In univariate analysis ‘true’ interval carcinomas were 
significantly larger (OR 7.2, 95% CI 1.8-28.1) and less frequently ER (OR 0.3, 
95% CI 0.1-0.9) and PR (OR 0.3, 95% CI 0.1-1.0) positive. In multivariate analysis 
‘true’ interval carcinoma was independently associated with larger tumours 
(OR 7.0, 95% CI 1.4-36.2). A trend towards ER negativity was found (OR 0.3, 
95% CI 0.1-1.1). ‘True’ interval carcinomas showed a trend towards a decreased 
relapse free survival (HR 1.7 95% CI 0.9-3.1). Although ‘true’ interval carcinomas 
were significantly larger than screen detected- / missed interval carcinomas it 
remains challenging to find parameters that determine this difference between 
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Introduction
From 1989 till 1997 a nation-wide breast cancer screening programme 
has gradually been implemented in The Netherlands.1 Starting as a biennial 
screening mammography for women aged 50-69, in 1999 the programme was 
also offered to women aged 70-75 years. The attendance rate is over 80% 
in the northern part of The Netherlands. The introduction of the screening 
programme has led to a substantial decrease in the rate of advanced breast 
carcinoma and to a breast cancer mortality decline of almost 30% in the 
screened and non-screened population.2 Despite the participation in the 
screening programme, a number of women still present with a clinically 
symptomatic carcinoma between two screening moments, a so-called interval 
carcinoma. In participants in the Dutch Breast Cancer Screening Programme, 
36% of the tumours emerge as interval carcinomas3 and there is discussion 
if interval carcinomas differ from screen-detected tumours biologically and 
should therefore deserve a different, perhaps more aggressive treatment.4 
Over the years many studies have been conducted on the differences between 
interval- and screen detected carcinomas.5-16 Comparison of these studies is 
difficult, because of the great heterogeneity in screening group, screening 
interval and study design. Therefore in this analysis a very homogeneous 
group of postmenopausal women is studied. All women presented with an 
invasive ductal carcinoma and participated in the breast screening programme 
(as confirmed by the Northern Netherlands Comprehensive Cancer Centre). The 
patients’ screening mammograms were re-reviewed in order to differentiate 
between ‘true’ interval carcinomas and false negative mammograms (missed 
carcinomas). We studied the expression of conventional tumour progression 
related biological markers (estrogen receptor (ER), progesterone receptor 
(PR), HER2/neu and p53), radiological characteristics (breast density, tumour 
outlining and calcifications) and follow-up data hypothesizing that if ‘true’ 
interval carcinomas are indeed a more aggressive subgroup of carcinomas, 
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Material and methods
Definitions
Screen detected carcinoma: a carcinoma detected in the screening 
programme. 
‘Missed’ carcinoma: a clinically detected carcinoma that occurred between 
two screening moments with a visible lesion on re-reviewing of the screening 
mammogram.
Interval carcinoma: a clinically detected carcinoma that occurred between 
two screening moments after a ‘true’ negative screening mammogram.
Patients
99 consecutive post menopausal women from who participation in the 
biannual breast screening programme could be confirmed by the Northern 
Netherlands Comprehensive Cancer Centre and who were treated between 
01-01-1996 and 31-12-2001 at the University Medical Centre Groningen for 
a primary operable invasive ductal carcinoma of the breast as defined by 
the WHO classification17 were retrospectively included in this study. Seven 
patients were excluded; one patient because she was already in clinical 
follow-up for an earlier in-situ lesion and six patients because their screening 
mammograms were not available for re-reviewing. Therefore the Patient and 
tumour characteristics and data on follow-up were obtained retrospectively 
from hospital records and are summarized in table 1. Histology was reviewed 
on the original hematoxylin- and eosin stained section. The median follow-
up was 61 months (range 6.3 – 106.4). Follow-up was performed according 
the follow-up guidelines of the Northern Netherlands Comprehensive Cancer 
Centre and consisted of a yearly mammogram in the first five years of follow-
up and clinical examination (quarterly in the first year of follow-up, biannually 
in the second year and annually the third to fifth year. After 5 years patients 
are referred back to the screening programme.18 During follow-up 4 patients 
developed a local recurrence after a median follow-up of 26.7 months. 11 
patients developed distant metastasis after a median follow-up of 27.3 months. 
In total 14 patients presented with a relapse with a median relapse free 
survival of 26.2 months. 5 patients died related to breast cancer with a median 
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Re-reviewing of mammograms
The original screening mammogram of all patients was re-reviewed by two 
of the authors (GJdH and RP), who are both experienced screening radiologists, 
in order to differentiate between ‘true’ interval carcinomas and interval 
carcinomas as a result of a false negative screening mammogram (missed 
carcinomas). A consensus reading was performed. The following criteria were 
used: type 1, nothing to be seen; type 2, minimal signs only in retrospect; type 
3, significant abnormality. Type 3 tumours were considered missed carcinomas. 
There was a maximum bias because both radiologists knew the inclusion 
criteria and question of the study. Breast density was scored on clinical 
mammograms by one of the authors (RP) using the Breast Imaging Reporting 
and Data Systems (BIRADS) classification for breast density.19 
Tissue Microarray Construction 
From the patient’s tumour paraffin block, three 0.6 mm core samples of the 
most representative tumour area were included in a tissue microarray. The 
technique of tissue microarray production has been described and validated 
for breast carcinoma by others.20; 21 In brief, the most representative tumour 
area was marked on the original hematoxylin- and eosin stained section. Using 
this section as an orientation, three 0.6 mm core punches were taken from 
the selected area in the donor blocks and mounted in a recipient block, using 
a manual tissue microarray device (Beecher Instruments, Silver Springs, MD, 
USA).
Immunohistochemistry
Immunohistochemistry for ER, PR, Her2/neu and p53 was performed 
on sections from the tissue array. The antibodies and antigen retrieval 
methods used are summarized in table 2. The immunostaining protocol 
was as follows: sections were deparafinized in pure xylene, rehydrated in 
decreasing concentrations of ethanol and washed in distilled water. Antigen 
retrieval was performed. The endogenous peroxidase reaction was blocked by 
incubating in 3% perhydrol for 30 minutes. The primary antibody diluted in 
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after which the secondary (biotinylated rabbit anti mouse, DAKO, 1:100 diluted 
in PBS containing 1% BSA and 1% AB-serum) and tertiary (biotinylated swine 
anti rabbit, DAKO, 1:100 diluted in PBS containing 1% BSA and 1% AB-serum) 
antibodies were incubated for 30 minutes each. Visualisation was performed 
using the diaminobenzidine tetrahydrochloride / peroxidase reaction. 
Counterstaining was performed using haematoxylin. Sections were dehydrated 
using rising concentrations of alcohol and were mounted. 
Evaluation of immunohistochemistry
Antibody staining was scored by one investigator (BvdV), under supervision 
of an experienced breast pathologist (JW), who randomly verified the scoring. 
ER, PR and p53 were graded based on the percentage of tumour cells showing 
positive nuclear staining. ER and PR were considered positive if nuclear 
staining was present in >10% of the cells, and p53 was considered positive 
in case of a substantial percentage of positively stained nuclei (>30%). Her-
2/neu expression was graded as recommended by the HercepTestTM scoring 
guidelines: 0: no staining at all or membrane staining in <10% of the tumour 
cells; 1+: a faint/barely perceptible partial membrane staining in >10% of the 
tumour cells; 2+: weak to moderate complete membrane staining in >10% of 
the tumour cells; 3+: strong complete membrane staining in >10%. Her-2/neu 
was considered to be overexpressed if the score was 3+. 
Data analysis
Data analysis was performed using the SPSS 14.0.2 statistical package (SPSS 
inc., Chicago, IL, USA). An univariate logistic regression analysis was performed 
to assess the odd ratios (OR) of clinico-pathological variables and biomarkers 
in ‘true’ interval carcinoma versus screen detected- / missed carcinoma. All 
parameters with an OR of 3.0 or higher in the univariate logistic regression 
analysis were then entered into a stepwise multivariate logistic regression 
analysis. A Cox regression analysis was performed to assess relapse free- and 
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Results
Tissue cores from all cases were successfully included in the TMA. 
Immunohistochemistry was assessable in 90 cases (98,0%) for p53, in 88 
(96,0%) for Her2/neu and ER, and in 87 cases (95%) for PR.
The results from the re-reviewing of the mammograms are shown in Table 
1. 16 of the 23 cases marked as interval carcinomas, were retrospectively 
‘true’ interval carcinomas. 7 cases showed a retrospectively visible lesion on 
the screening mammogram. Most of those lesions (5/7) were now classified 
as ‘uncertain benign’ where they had earlier been classified as ‘benign’. Two 
cases were now classified as ‘malignancy suspected’. One of those cases had 
originated in very dense breast tissue which might have caused the judgement 
error. A clinical mammogram was available in 88 cases (96%). Breast density 
was evenly distributed between ‘true’ interval carcinomas and screen detected- 
/ missed carcinomas. 
Univariate analysis
The results of univariate logistic regression analyses of clinico-pathological 
parameters and biomarkers in ‘true’ interval- versus screen detected- / missed 
carcinomas are shown in table 3. Most parameters did not differ between 
both groups. ‘True’ interval carcinomas were significantly larger (OR 7.2, 95% 
CI 1.8-28.1, p=0.005) and were less often ER positive (OR 0.3, 95% CI 0.08-0.9, 
p=0.034). A trend towards PR negativity (OR 0.3, 95% CI 0.1-1.0, p=0.06) was 
found in ‘true’ interval carcinomas. 
Multivariate analysis
Table 4 shows the results of a multivariate analysis. Tumour size was 
significantly associated with ‘true’ interval carcinoma (HR 5.1, 95% CI 1.2-21.0, 
p=0.02). A trend towards ER negativity was also found (HR 0.3, 95% CI 0.08-1.2, 
p=0.08). PR was eliminated from the equation.
Clinical outcome
The Cox regression analysis showed a trend towards decreased relapse free 
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Discussion
This study compared clinical, pathological and radiological variables, the 
expression of conventional biomarkers and follow-up data of ‘true’ interval 
carcinomas versus screen detected- and missed carcinomas, hypothesizing 
that ‘true’ interval carcinomas express parameters of aggressive behaviour 
more abundantly. ‘True’ interval carcinomas were larger and showed a trends 
towards ER negativity and decreased relapse free survival.
In table 6 the results from a literature search on studies assessing 
differences between interval- and screen detected breast carcinomas 
conducted in postmenopausal women are shown. When comparing the results 
from the studies that defined ‘true’ interval carcinoma with the current study 
our finding of increased tumour size and decreased ER expression in ‘true’ 
interval carcinoma confirms some of the results of those studies. Some studies 
also found differences in the number of positive axillary lymph nodes and 
tumour grade, findings that we could not confirm. Those findings were never 
confirmed in multivariate analysis however.
Several restrictions apply when comparing studies conducted on the 
differences between interval- and screen detected carcinomas. First, there 
is large heterogeneity in study groups, screening interval, type of breast 
cancer studied and study design. Second, most studies, including the current 
one, comprise a small study group. One might argue that these study 
groups are too small and heterogeneous to gain sufficient statistical power 
to find differences between screen detected and interval carcinomas. To 
avoid heterogeneity in type of breast carcinomas and the patient population 
studied, we focused on postmenopausal women in the screening programme, 
presenting with an invasive ductal carcinoma as defined by the WHO 
classification17, as this is by far the most common type of breast cancer. Third, 
most studies use univariate logistic regression analysis to study differences, 
making their findings more susceptible to biases.22 Therefore we performed a 
stepwise multivariate logistic regression analysis to correct for confounding 
factors. Fourth, the definition of an interval carcinoma differs between studies. 
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moments as an interval carcinoma. This is a correct definition of interval 
carcinoma when looking at the sensitivity of the screening programme as a 
whole. A portion of those interval carcinomas, however, are in fact significant 
lesions that should have been referred. These tumours are not detected in the 
interval between two screening moments because of their biological behaviour, 
but due to restrictions of the screening programme. Therefore, in the current 
study screening mammograms were re-reviewed in order to differentiate 
between ‘true’ interval carcinomas and interval carcinomas as a result of a 
false negative screening mammogram. We defined an interval carcinoma as a 
clinically detected carcinoma that occurred between two screening moments 
after a ‘true’ negative screening mammogram. Using this definition of interval 
carcinoma the sensitivity of the screening mammogram as a test for detecting 
breast carcinoma can be assessed. The programme sensitivity of the Dutch 
screening programme was 65% in the nationwide evaluation of the programme 
(meaning that for every two carcinomas discovered in the screening 
programme in the two years between screening moments another carcinoma 
is discovered clinically). In our series the programme sensitivity was 75% 
(using the first definition described above). It is plausible that this difference 
is caused by the selection of the study group (only invasive ductal carcinomas 
were included). The Dutch National Evaluation Team Breast Cancer Screening 
(LETB) has estimated that in general (ductal carcinoma in situ and lobular 
carcinoma included) from all the interval carcinomas approximately 50% is a 
‘true’ interval carcinoma. 25% of the interval carcinomas show a clear lesion, 
for which a patient should have been referred for additional diagnostics, on 
re-reviewing of the screening mammography, and a further 25% show ‘minimal 
signs’, that are only suspicious with the knowledge of a clinically discovered 
interval carcinoma. The percentage of ‘true’ interval carcinomas in this series 
was 30.4%, which is comparable to those estimations.
‘True’ interval carcinomas were five times more often larger sized (>2 cm) 
tumours in our series. Several explanations for the increased size of interval 
carcinomas have been suggested in literature. First, interval carcinomas have 
been associated with dense breast tissue, with poor outlining, and with 
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with dense breasts become clinically apparent after a negative screening 
mammogram, they are more ahead in their natural history compared to screen 
detected carcinomas and are therefore larger, a phenomenon called lead time 
bias.25 In our series breast density was evenly distributed between screen 
detected- / missed carcinomas and ‘true’ interval carcinomas. Second, several 
studies suggest that interval carcinomas are rapidly proliferating tumours. 
Several different parameters for proliferation are used in these studies. Two 
studies found increased mitotic count and Ki-67 antigen expression in interval 
carcinomas.7; 10 One of those studies however was performed a heterogeneous 
group of breast carcinomas, including lobular carcinomas, which may have 
confounded the results of this study somewhat. Ki-67 immunohistochemistry 
was not performed in this series, because this expression is very 
heterogeneous in ductal breast carcinoma and therefore difficult to interpret 
on TMA. Others used fraction of tumour cells in the S-phase fraction of the 
cell-cycle as a marker for proliferation and found an increase of this fraction 
in interval carcinomas.11; 13 In this study we used the Bloom-Richardson scoring 
system, of which mitotic count is a part, to assess grade of differentiation as 
a marker for proliferation.26 We did not find a difference between both groups 
of this study. There are other biological factors outside proliferation rate that 
may play a role in the development of breast carcinoma and may explain 
the difference in size between ‘true’ interval- and screen detected- /missed 
carcinoma. For example, tumour cells from ‘true’ interval carcinomas may be 
less susceptible to apoptosis. One study assessing the number of apoptotic 
cells in interval- and screen detected carcinomas did not find a difference 
between both groups.10 In addition, tumours that have a higher angiogenic 
potential may grow faster due to reduced tumour cell death. Another key role 
player is the amount of tumour stroma induced which will affect significantly 
the size of tumours, especially of invasive ductal carcinomas which are 
known for their highly variable desmoplasia inducing potential27. It remains 
to be established if and to which extent these explanations contribute to 
the difference in growth rate between screen detected carcinomas / missed 
carcinomas and ‘true’ interval carcinomas. 
It is assumed that 50 to 75% of the tumours discovered in the first screening 
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often ER and PR positive. We found that screen detected- / missed carcinomas 
were significantly more often ER positive in univariate analysis, a result that 
is confirmed by other studies.7 This association only showed a trend towards 
significance in multivariate analysis, probably due to the relatively small 
sample size of this study. These relatively less aggressive tumours might also 
explain the trend towards increased relapse free survival we found for screen 
detected carcinomas.
In conclusion, in this small consecutive and homogeneous study group of 
postmenopausal women with invasive ductal breast carcinoma we found a 
significant difference in tumour size between ‘true’ interval- versus screen 
detected- / missed carcinomas in multivariate analysis. ER expression differed 
significantly between both groups in univariate analysis. It remains challenging 
however to find parameters that determine this difference between the ‘true’ 
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Tables
Table 1. patient and tumour characteristics. 
n %
Age at diagnosis
median (range) 60.2 50.2 – 74.8
Detection
     screen detected 
     interval (‘true’)







Mammographic breast density on diagnostic mammography 
(BIRADS)
     I
     II
     III
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Table 2. Antibodies and antigen retrieval methods.
antibody clone supplier dilution antigen retrieval
ER 6F11 Ventana * Tris/HCL 0.1 M (pH 9.5) 30’ 98oC microwave
PR 1A6 Ventana * Tris/HCL 0.1 M (pH 9.5) 30’ 98oC microwave
Her2/neu CB11 Ventana * Tris/HCL 0.1 M (pH 9.5) 30’ 98oC microwave
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Table 3. Univariate logistic regression analysis of clinico pathological 
variables and biological markers in ‘true’ interval carcinoma vs screen 




Age at diagnosis (n=92) 1.0 (0.9-1.1) 0.808
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 Table 4. Independent predictors of ‘true’ interval carcinoma.(n=82). 













Table 5. Relapse free and overall survival for ‘true’ interval carcinoma vs 
screen detected- / missed carcinoma. 
HR 95% CI p-value
Relapse Free Survival(n=91)
     SD/M carcinoma




     SD/M carcinoma
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Abstract
HER2 overexpression in breast cancer is associated with worse clinical 
outcome. To select patients for anti-Her2 based therapy immunohistochemistry 
is commonly performed as a first step to assess Her2 status. However, 
interobserver and interlaboratory variability can compromise adequate 
assessment of Her2 status significantly. In addition, immunohisto-chemistry 
does not always result in an unambiguous test result requiring additional 
testing for Her2 gene amplification. This study aimed to improve the reliability 
of Her2 immunohisto-chemistry by using rabbit monoclonal antibody 4B5 
as an alternative of mouse monoclonal antibody CB11 routinely used in 
our laboratory. Therefore 283 breast adeno-carcinomas were included in a 
tissue microarray. Immunohistochemistry using the 4B5 and CB11 antibodies, 
and fluorescence- and chromogenic in situ hybridisation (FISH or CISH) 
were performed. Immunohistochemistry was scored by two independent 
investigators. We found that 4B5 staining was more distinct than CB11 staining. 
For the CB11 staining there were 12% (BV) and 5% (JW) 2+ scores compared 
to 4% (BV) and 2% (JW) for 4B5. There was a strong trend towards higher 
interobserver agreement for 4B5 compared to CB11 (4B5: κ 0.87, 95% CI 0.79– 
0.96; CB11: κ 0.77, 95% CI 0.66 – 0.88). There were no significant differences 
in sensitivity, specificity, and predictive values between CB11 and 4B5. Our 
results indicate that the 4B5 antibody provides more robust assessment 
of immunohistochemical Her2/neu status and will reduce the number of 
gene amplification tests compared to CB11. However, for tumours with a 2+ 
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Introduction
The status of the Her2 receptor is an important factor in prognosis and 
treatment choice in primary breast carcinoma.1 Mortality and recurrence are 
reduced in patients with Her2/neu positive breast carcinoma that receive 
adjuvant therapy with both the humanized anti-Her2/neu monoclonal antibody 
therapy trastuzumab and chemotherapy.2-5
Trastuzumab therapy however is associated with cardiotoxicity, in 2 to 
4.7% percent of patients when used as monotherapy, but in up to 27% 
when given concomitantly with anthracycline and cyclophosfamide therapy.6 
Therefore this treatment is only given to patients with confirmed Her2/
neu positive breast carcinoma and adequate left ventricle ejection fraction. 
Several methods are used to assess Her2/neu status in breast cancer. 
Measurement of gene amplification using fluorescence in situ hybridisation 
(FISH) or chromogenic in situ hybridisation (CISH) is considered to be 
the ‘gold standard’ in the assessment of Her2/neu status.7-9 However the 
most commonly used first line method to determine Her2/neu status is 
immunohistochemistry. Immunohistochemistry is relatively inexpensive and 
a routinely used technique in pathology laboratories which makes it easy to 
implement. Immunohistochemistry results in a Her2/neu score ranging from 0 
(no expression) to 3+ (strong complete tumour cell membrane expression).10 
This semi-quantitative scoring system does not always result in a clear positive 
or negative Her2/neu amplification status. It is generally agreed that when a 
Her2 score is ambiguous (2+ score) a gene amplification measurement has 
to be performed. 7; 11; 12 Another setback of Her2 immunohistochemistry is the 
significant interobserver variation and poor interlaboratory reproducibility.13-16 
Since accurate diagnostic assessment of HER2/neu is essential for the 
appropriate application of trastuzumab containing treatment regiments, 
the concordance between immunohistochemistry and the ‘gold standard’ 
gene amplification assessment needs to be as high as possible. Therefore 
immunohistochemistry staining should be improved to optimize accurate 
estimation of the HER2/neu status.
In recent years, rabbit monoclonal antibodies have been developed 
which show higher affinity and specificity than mouse monoclonal or rabbit 
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Her2 immunohistochemistry reliability in our laboratory we tested the potential 
of the rabbit monoclonal antibody 4B5 directed against Her2/neu as an 
alternative to the mouse monoclonal CB11 directed against Her2/neu using 
both a CISH array for Her2/neu and a Her2/neu FISH array as reference.
Materials and Methods
Patients
To determine the size of the series, a power analysis was performed. In this 
power analysis, we considered HER2/neu immunohistochemistry negative if 
the staining pattern and intensity is equivalent to score ‘0’ or ‘1+’ and positive 
if it is equivalent to score ‘3+’. 2+ cases are not taken into account in this 
power analysis, because they are clinically uninformative. We assumed 10% 
2+ cases. We also assumed that the rabbit monoclonal antibody has a better 
sensitivity and specificity than the mouse mouse monoclonal antibody CB11. 
Furthermore a loss of 20% cases due to unavailability of tumour material 
or uninterpretability of one or more of the stainings was assumed. Based 
on these assumptions, a sample size of 280 was required to achieve 90% 
power to detect an odds ratio of 3.000 using a two-sided McNemar test with 
a significance level of 0.05000. The odds ratio is equivalent to a difference 
between two paired proportions of 0.100 which occurs when the proportion 
T
N
 negative versus T
O
 positive is 0.150 and the proportion T
N
 positive versus 
T
O
 negative is 0.050. 283 consecutive female patients treated for a primary 
operable invasive carcinoma of the breast at the University Medical Center 
Groningen between January 2002 and December 2005 were included in 
this study. Afterwards 8 patients were excluded because no representative 
material was available in the tissue microarray blocks. The analyses have 
been performed on the resulting group of 275 patients. Patient and tumour 
characteristics were obtained retrospectively from hospital records and are 
summarized in table 1. 
Tissue microarray construction 
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most representative tumour area were included in a tissue microarray. The 
technique of tissue microarray production has been described and validated 
for breast carcinoma by others.19; 20 In the latter study authors showed that 
the concordance between the tissue microarray with the whole tissue sections 
was over 97% percent if three 0.6 mm core samples per tumor were included 
in the TMA. In brief tissue microarrays were compiled as follows: the most 
representative tumour area was marked on the original hematoxylin- and 
eosin (H&E) stained section. Using this section as an orientation, three 0.6 
mm core punches were taken from the selected area in the donor blocks 
and mounted in a recipient block, using a manual tissue microarray device 
(Beecher Instruments, Silver Springs, MD, USA). In total seven tissue microarray 
blocks, each containing tumour cores from 40 to 50 patients, were made. Using 
a standard microtome 3μm sections were cut from these tissue microarray 
blocks. 
Immunohistochemistry, FISH and CISH
Immunohistochemistry for rabbit monoclonal antibody 4B5 (PATHWAY® 
HER-2/neu (4B5) rabbit monoclonal antibody, Ventana Medical Systems, 
Illkirch, France) and mouse monoclonal antibody CB11 (PATHWAY® HER-2/neu 
(CB11) mouse monoclonal antibody, Ventana Medical Systems, Illkirch, Cedex, 
France) was performed on the tissue microarray sections using the automated 
Benchmark® platform (Ventana Medical Systems, Illkirch, Cedex, France) and 
according to the manufacturers recommendations. FISH (PathVysion HER-2 
DNA Probe Kit, Vysis Inc., Downers Grove, IL, USA) and CISH (SPoT-Light® HER2 
CISH™ Kit, Zymed, Carlsbad, CA, USA) assays were performed according the 
manufacturers recommendations.
Evaluation of immunohistochemistry, FISH and CISH
Scoring of the CB11 and 4B5 immunohistochemistry stainings was performed 
independently by an experienced pathologist (JW) and a senior resident (BV). 
Her-2/neu expression was graded as recommended by the HercepTestTM scoring 
guidelines: 0: no staining at all or membrane staining in <10% of the tumour 
cells; 1+: a faint/barely perceptible partial membrane staining in >10% of the 
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the tumour cells; 3+: strong complete membrane staining in >10%. 
FISH was scored according the ASCO guidelines: the ratio of 20 cells was 
calculated. A ratio <1.8 was considered negative, a ratio >2.2 was considered 
positive. For the equivocal cases another 20 cells were counted. In these cases 
a ratio ≥2 was considered positive. A ratio <2 was considered negative. For CISH, 
tumours with at least 5 signals in more than 50% percent of the tumour cells 
were considered positive.
Data analysis
All statistical analyses were performed using the SPSS 14.0 software 
package.
The feasibility of both staining methods was compared. The number of 
informative test results and the number of 2+ scores were calculated for 
each of the staining methods. Agreement between immunohistochemistry 
results and in-situ hybridisation results were calculated in a cross tabulation 
using a Pearson chi-square test. Sensitivity and specificity were calculated 
using two methods, including and excluding 2+ scores. In the first method 2+ 
scores were considered a positive test result. This method is most commonly 
used in literature and was performed to compare our results to those found 
in other studies. 2+ scores are however clinically uninformative and were 
therefore eliminated from analysis in the second method. The positive 
predictive value (PPV) was calculated by dividing the number of cases is the 
immunohistochemistry 3+ group with amplification on FISH or CISH by the 
total number of cases with an immunohistochemistry 3+ score. The negative 
predictive value (NPV) was calculated by dividing the number of cases 
immunohistochemistry score 0 or 1+ without amplification on FISH or CISH by 
the total number of patients with an immunohistochemistry 0 or 1+ score. For 
sensitivity, specificity and predictive values a 95% CI interval was calculated. 
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Results
Feasibility
In figure 1 an example of both a 4B5 and a CB11 staining for 1 case is 
shown. In general the 4B5 staining was more distinct compared to the CB11 
staining. Also the 4B5 staining showed less non-specific cytoplasmic staining.
Test characteristics
Of the 275 cases included 262 (95%) of the cases were adequately 
represented in the tissue microarray. Immunohistochemistry could be 
evaluated in 83% (JW) and 90% (BV) of the cases for 4B5, in 87% (JW) and 91% 
(BV) of the cases for CB11. Differences in evaluation percentages between 
authors have been caused by disagreement on the overall percentage of 
tumour available in the core punches and the relative percentages of invasive 
tumour vs. in-situ tumour available in the core punches. FISH could be 
evaluated in 90% and CISH in 92% of the cases. 
Agreement
In 230 of the 240 assessable cases (96%) there was agreement between FISH 
and CISH scoring (κ 0.837, 95% CI 0.737 – 0.937) . There was an agreement of 
80% (BV) and 81% (JW) between the scoring results of 4B5 and CB11 (table 2). 
The disagreement between scores is mainly caused by the 2+ scores. There 
was a reduction of more than 50% for the number of cases scored as 2+ when 
comparing CB11 with 4B5; respectively 28 cases (12%) vs 13 cases (4%) (BV) 
and 12 cases (5%) vs 5 cases (2%) (JW). When excluding the 2+ cases from 
analysis there was no difference between both antibodies for the classification 
of cases as amplified or not amplified (McNemar’s test p=1.0, data not 
shown) e.g. there would be no clinical consequences when using either of 
the antibodies. In tables 3 and 4 the results for the concordance between 
immunohistochemistry and respectively FISH and CISH are shown. Sensitivity 
(including and excluding 2+ scores), specificity (including and excluding 2+ 
scores), PPV and NPV of 4B5 and CB11 using both FISH and CISH as reference 
are shown in table 5. Sensitivity, specificity, PPV and NPV did not show any 
significant differences between both antibodies and between both observers. 
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scores) for the lesser experienced observer (BV) between 4B5 and CB11: (4B5: 
0.99, 95% CI 0.95-1.0; CB11: 0.93, 95% CI 0.88-0.96). Although not significant, 
there was a trend towards an increased concordance between observers for 
4B5 compared to CB11 (4B5: κ 0.87, 95% CI 0.79– 0.96; CB11: κ 0.77, 95% CI 0.66 
– 0.88) (Table 6). 
Discussion
In this study we tested the potential of the 4B5 anti Her2 rabbit monoclonal 
antibody by comparing it to the CB11 anti-Her2 mouse monoclonal antibody 
on a consecutive series of invasive breast adenocarcinomas using both FISH 
and CISH as reference. We found that 4B5 staining was more distinct and 
showed less nonspecific cytoplasmic background staining, which led to a more 
than 50% reduction of the number of 2+ scores for 4B5 compared to CB11. 
In this well powered study we found no significant differences in sensitivity, 
specificity, predictive values and interobserver concordance between 4B5 and 
CB11. However there was a trend towards a higher specificity for 4B5 for one 
of observers (BV) and a trend towards an increased interobserver concordance 
for 4B5. The – non-significant - differences in the test results of both observers 
would have no consequences for clinical decision making regarding the Her2 
status of the carcinomas investigated.
Gene amplification measurement is considered to be the ‘gold standard’ 
for Her2/neu status assessment7-9 although it suffers from variability between 
institutes21; 22 and the sensitivity varies between detection methods used.9 
Traditionally gene amplification measurement has been performed using 
FISH assays for Her2/neu gene amplification. This method however has 
several disadvantages: FISH is expensive, is time demanding8, is not readily 
accommodated in most pathology laboratories and is accompanied by technical 
challenges23. More recently CISH assays have been developed. Instead of the 
fluorogens used in FISH, this technique uses chromogens. This has several 
advantages24: where FISH requires a fluorescence microscope for interpretation, 
CISH can be interpreted using a normal bright field microscope. CISH allows 
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heterogeneity and gene copy number in different components of the tumour 
(an invasive and an in-situ component). Also FISH signals are labile and fade 
over time, but CISH produces a permanent staining. 
Many authors have compared CISH with FISH (reviewed in 24). Most studies 
find an agreement of both methods of more than 90 percent. In a multicenter 
study, where pathology laboratories blindly performed CISH on cases from 
each other this method was validated.25 That study also reported an intra- and 
interobserver agreement of over 90 percent and concluded that CISH is a viable 
alternative to FISH. In the current study the agreement between FISH and 
CISH was 96 percent, which is in line with the conclusions of those previous 
studies. Of the 10 discordant cases in our series 5 cases contained an in situ 
component. This tumour heterogeneity might have led to the discordance 
because distinction between the invasive and the in-situ component can be 
difficult in FISH where tumour morphology is not readily recognized in all 
cases. 
Most pathology laboratories use immunohistochemistry to assess Her2/neu 
status. Immunohistochemistry is not only less expensive than in situ methods, 
there is also much experience with immunohistochemistry, which makes 
it a method that is easily implemented in the daily practice of pathology 
laboratories. Immunohistochemistry however, has several disadvantages: 
immunohistochemistry is scored semiquantitively which leads to a 0 – 3+ 
score rather than to a clear amplification / no amplification outcome. Scores 
0 and 1+ are considered non-amplified and score 3+ is considered amplified. 
An ideal Her2 antibody has a low number of indeterminate (2+) cases and a 
high PPV and NPV. We found that 4B5 staining compared to CB11 was more 
distinct and showed less nonspecific cytoplasmic background staining. This 
has led to an increase in interobserver concordance (4B5: κ 0.87, 95% CI 
0.79– 0.96; CB11: κ 0.77, 95% CI 0.66 – 0.88) that showed a trend towards 
significance. Interobserver concordance is essential because it has far reaching 
consequences for the choice of therapy regimen and response to therapy. A 
few studies have assessed interobserver concordance for CB11. Two of those 
studies found an interobserver concordance of 0.74 which is comparable to 
our results (0.77).13; 15 In a study by Tsuda et al an interobserver concordance 
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calculate concordance however. The concordance of 0.87 we found for 4B5 is 
considered almost perfect26, which underlines that 4B5 is a safe method to 
assess Her2 status in breast cancer. To our knowledge no other studies have 
assessed interobserver concordance for 4B5. Interlaboratory concordance 
was not assessed in this study. One study mentions a perfect interlaboratory 
concordance on a very limited number of cases.27 Future studies are needed to 
assess this issue. 
In this series a cut-off of 10% staining was used for scoring Her2 
immunohistochemistry. This cut-off was chosen based on Dutch guidelines, 
which differ from the ASCO guideline using a cut-off of 30%. However, this 
difference in cut-off did not cause a significant change in the results.
The number of cases that were scored as 2+ was lower for 4B5. For 
4B5 observers scored 4% and 2% 2+ cases; for CB11 this was 12% and 5%. 
The number of CB11 2+ cases in this study is comparable the numbers in 
literature were the number of cases scored 2+ using an mouse monoclonal 
antibody ranges from 2 to 20.5%, and is usually is around 10%.28 We expect 
that the introduction of 4B5 will reduce the number of FISH or CISH assays 
that will have to be performed, which leads to a reduction in costs. In this 
well powered study this decrease of indeterminate cases did not lead to a 
significant difference in sensitivity, specificity, or predictive power between 
CB11 and 4B5. Small numbers did not allow a statistically reliable subgroup 
analysis to assess differences in sensitivity, specificity and predictive values 
for the immunohistochemistry 2+ cases of both antibodies using FISH or CISH 
as a reference. In table 7 the results from other studies assessing sensitivity, 
specificity and predictive values of CB11 are shown. Most studies considered 
2+ cases to be amplified for the calculations. As discussed before 2+ cases 
correlate with gene amplification very poorly.7; 11; 12 We believe that 2+ cases 
should be excluded from analysis when assessing sensitivity, specificity and 
predictive values. The values for sensitivity, specificity and predictive values 
we found in this study are comparable to those found in literature. Powell et 
al performed a study comparing 4B5 with CB11 using FISH as a reference in two 
subsets of cases, one containing samples from a single institution, and one 
containing samples from a multicenter tissue bank.27 In that study the levels 
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current study. However, these differences were not significant for the subset 
best comparable to the current study group, i.e. the single institution subset.  
PPV and NPV show no significant difference between both antibodies, which 
underlines that the lower number of indeterminate cases which led to the 
increase in sensitivity and specificity did not cause a loss of predictive value 
of the test. In a group of 199 invasive breast cancers Egervari et al compared 
the 4B5 antibody with a number of antibodies including the CB11 antibody 
using FISH as a reference.29 When recalculating their results using the method 
described earlier they a sensitivity (0.76 (0.5-0.92)), specificity (0.99 (0.96-1.0)), 
PPV (0.93 (0.64-1.0)) and NPV (0.97 (0.93-0.99)) that does not differ significantly 
to our results. Although they suggest a lower sensitivity of 4B5 compared to 
CB11 this result is not significant (table 7). 
In conclusion we showed that the novel 4B5 rabbit monoclonal anti-Her2/
neu antibody has a good agreement with both FISH and CISH and has a 
sensitivity, a specificity and predictive values comparable to CB11. We found 
a reduction of more than 50% in the number of indeterminate cases for 
4B5 and an increase in interobserver concordance. Our results indicate that 
immunohistochemistry using the 4B5 antibody provides more robust and hence 
more reliable assessment of the Her2/neu status detection and will reduce the 
number of gene amplification tests compared to the CB11 antibody. However, 
for patients with a 2+ score additional gene amplification measurement using 
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Tables
Table 1. Patient and tumour characteristics.
n (%)
Age at diagnosis






Pathological tumour size (mm)




























Validation of the 4B5 rabbit monoclonal antibody  
in determining Her2/neu status in breast cancer
Table 2. Correlation of 4B5 and CB11 for observer BV (A) and JW (B).
A
CB11 BV
4B5 BV 0 1 2 3 total
0 149 (95) 20 (50) 4 (14) 0 (0) 173 (71)
1 7 (4) 19 (48) 14 (50) 0 (0) 40 (16)
2 1 (1) 1 (2) 8 (29) 0 (0) 13 (4)
3 0 (0) 
 
0 (0) 2 (7) 19 (100) 21(9)




4B5 JW 0 1 2 3 total
0 106 (96) 28(35) 0 (0) 0 (0) 134 (60)
1 5 (4) 51 (64) 6 (50) 0 (0) 62 (28)
2 0 (0) 1 (1) 4 (33) 0 (0) 5 (2)
3 0 (0) 0 (0) 2 (17) 20 (100) 22 (10)










Validation of the 4B5 rabbit monoclonal antibody  
in determining Her2/neu status in breast cancer




























































































































































































































































































































































































































Validation of the 4B5 rabbit monoclonal antibody  
in determining Her2/neu status in breast cancer



































































































































































































































































































































































































































Validation of the 4B5 rabbit monoclonal antibody  
in determining Her2/neu status in breast cancer
Table 5. sensitivity, specificity and predictive values for 
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Table 6. Concordance between observers.
Kappa 95% CI
4B5 0.87 0.79 - 0.96
CB11 0.77 0.66 - 0.88
Table 7. Sensitivity, specificity, predictive and  
concordance for CB11 from literature.
Author Study  
size
Sens Spec Method PPV NPV
Kakar30 112 0.93(0.66-1.0)# 0.98 (0.90-1.0)# 2 0.88 (0.60-
0.98)#
0.99 (0.92-1.0)#








Press9 74 0.721 (0.56-
0.85)
1.00 (0.95-1.0) 1
Press21 64 0.95 (0.74-1.0) 0.84 (0.70-0.93) 1
Ricardo31 190 0.52 (0.37-
0.67)#




















Egervari29 199 0.83 (0.58-
0.96)#
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This thesis explored the possibilities of the tissue microarray technique in 
the evaluation and validation of new prognostic indicators in breast carcinoma. 
Although many biomarkers have been introduced over the years few have 
actually made it to clinical practice. A marker that looks promising in an initial 
study may show inconsistent or contradicting results in subsequent studies. 
Many possible causes for this problem are given (summarized in1): differences 
in methods and assays, sample sizes, inappropriate patient selection due 
to the availability of patient material and the quality of patient material. 
In addition to these general causes one of the biggest challenges in breast 
carcinoma biomarker validation studies is study group homogeneity. There are 
several reasons for this: the early breast cancer profiling studies, for example 
the study by Perou et al2, have shown us that breast carcinoma is not one 
entity but a very heterogeneous disease. Besides the histological subtypes 
of breast carcinoma that we knew, at least 3 different ‘intrinsic’ subgroups 
of breast carcinoma exist that cannotbe distinguished on histological criteria 
only: the ER positive types of breast cancer and at least two ER negative types: 
the basal type and the HER2 type of breast carcinoma.3  While a candidate 
biomarker may play a role in the biology of one of the subgroups, this role 
might not be there for all the others. A second reason is the wide variety of 
treatment combinations used in breast cancer treatment. It is very difficult 
to test and validate candidate biomarkers in large study groups that have all 
received the same treatment regimen.
Because of these problems REporting guidelines for prognostic studies 
evaluating tumour MARKers (REMARK) have been proposed by the NCI-EORTC.1 
The most important items of this guideline are: a clear study objective and 
hypothesis (with as prerequisite a formal power analysis); a description of the 
marker, the study group (inclusion and exclusion criteria) and the analytical- 
and statistical methods used; univariate analysis to show the relation between 
the marker and standard prognostic factors and outcome; multivariate analysis 
to show the relation of the marker, compared with standard prognostic factors, 
and outcome. In addition to this it is important that the design of biomarker 
studies in breast carcinoma aims to reduce tumour-, patient- and treatment 








With the introduction of the multigene profiles many authors believed 
that those profiles would replace conventional clinicopathogical parameters 
in the assessment of prognosis in breast carcinoma. Validation trails for the 
clinical use of the 21-gene Recurrence Score (Oncotype Dx) and the 70-gene 
profile (Mammaprint) in the assessment of breast cancer prognosis of ER 
positive breast cancer are currently ongoing.4,5 Although both profiles have 
almost no genes in common, it has been shown that both profiles are able 
to identify similar risk groups. It is suggested that prognosis in ER positive 
breast carcinoma (the subgroup in which both of the profiles have been 
developed) is strongly directed by tumour proliferation and that although the 
genes included in both profiles are completely different both gene sets are a 
derivative of tumour proliferation.3,6 Supportive evidence for this comes from a 
study by Cuzick et al who compared the 21-gene Recurrence Score with a score 
based on three commonly used immunohistochemical markers (ER, PR en 
HER2) combined with a proliferation marker (Ki-67).7 In this study both scoring 
systems were able to identify similar risk groups. While the validation of the 
prognostic gene profiles is ongoing it has become apparent that ‘classical’ 
prognostic indicators remain an independent predictive factor in breast cancer 
prognosis models.8 A recent study therefore developed a risk score based on 
a combination of the recurrence score of the Oncotype Dx profile with some 
classical prognostic indicators (age, tumour size and tumour grade.9 The results 
of that study look promising: using the combined score some patients may be 
re-classified from the intermediate- to the low risk group, i.e. some additional 
patients that might not benefit from adjuvant chemotherapy were identified. 
However, this model still has to validated in independent data sets.10
The tissue microarray technique offers the opportunity to study cells and 
tissue at the protein level in a high throughput fashion. Because proteins 
are the executors of the majority of cellular functions and because not all 
(approximately 70%) mRNA is translated into protein it is highly relevant to 
use and analyse protein expression as candidate markers in prognosis and 
prediction of treatment response. In addition, posttranslational modifications 
such as phosphorylation or protein cleavage may play a role in protein function 








tissue microarray technique is the combination of protein expression with 
histology; therefore the location of the protein expression can be studied. As 
we have shown in chapters 5 and 6, the location of protein expression can 
lead to divergent effects in tumour behaviour. The stroma of a tumour has 
long been thought of as a passive bystander that supports the tumour cells. 
Recently however it was found that alterations, especially in tumour stromal 
fibroblast, may play a pivotal role in tumour development (reviewed in12) . 
They may shape the tumour microenvironment with matrix metalloproteinases 
that degrade the extracellular matrix and may be able to secrete cytokines and 
growth factors that stimulate tumour growth. It would be very interesting to 
use protein-based techniques to study the expression of markers specifically in 
the tumour stroma. 
A problem of the currently used protein expression studies is that it can 
only be used to assess a small number of proteins, because only one protein 
can be evaluated in one test. This makes it unfit for genome wide screening 
studies. However, protein arrays compiled in much the same way as the DNA 
based techniques, with proteins fixed on a solid surface, are emerging. This 
makes it possible to assess the expression of large numbers of proteins in 
one experiment in a similar manner as the DNA based techniques.11 Other 
techniques that are emerging are functional analysis like Chip-on-chip 
technique, and kinome profiling which give a genome wide view of respectively 
the DNA-binding proteins and kinase activity. These analyses provide insight in 
the molecular pathways that are activated or deactivated within a tumour. With 
the growing number of therapeutic monoclonal antibodies that bind specific 
targets in a tumour cell, patients with a certain tumour genotypes, that lead 
to altered molecular pathways in a tumour cell, might benefit from a therapy 
that targets that specific alteration. Examples are the use of the EGFR inhibitor 
gefitinib or more recently the ALK inhibitor crizotinib in specific lung carcinoma 
patients, or targeted therapies for melanoma patients with a BRAF mutation.
In conclusion many high throughput methods for breast carcinoma have 
emerged in recent years. These methods have taught us much about the 
heterogeneity of breast cancer. Tissue microarrays can well be used to validate 
‘key’ markers from genome wide arraying studies in larger cohorts. The 








prognostic indicators, can aid to the development of clinically applicable 
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Breast carcinoma is the most common malignancy in women in the 
Western World. 'Classical' prognostic indicators like tumour size, tumour grade, 
estrogen receptor expression and Her2/neu receptor expression adequately 
predict outcome for large groups of breast carcinoma patients, but poorly 
predict outcome for the individual breast carcinoma patient. In recent years 
many new microarray techniques have been introduced to quickly assess the 
expression of many genes or proteins in one patient. One of these methods 
is the tissue microarray array technique. This technique makes it possible 
to compile material of tumours of up to 300 patients into one paraffin block, 
thereby enabling highly efficient testing of one protein in a large cohort of 
tumours in one experiment. The aim of this thesis, as formulated in chapter 
1, was to examine the possibilities of the tissue microarray technique in the 
evaluation of new prognostic and predictive markers at the protein level in 
breast carcinoma. 
In chapter 2 an overview of the most commonly used microarray methods 
(oligo- or cDNA arrays, CGH arrays, PCR arrays, and tissue microarrays) that are 
used to identify markers that are associated with tumour progression i.e. the 
development of metastatic disease, local recurrence or cancer related death is 
given. Oligo- and cDNA arrays are the most commonly used microarrays and 
make it possible to assess up to 50000 genes of interest in one experiment. 
Each experiment assesses a gene profile of one test sample. These techniques 
are very expensive (e.g. a single Mammaprint test costs €2,675,- (http://
www.mammaprint.nl, accessed on 02-12-2011) and complex which makes it 
is only possible to use them in relatively small study groups. PCR and tissue 
microarray on the other hand are techniques that more easily allow larger 
study groups, but only allow the assessment of one gene of interest in one 
experiment. Rather than competitive these techniques can be complementary 
to each other; while the DNA microarray techniques can well be used to 
generate hypotheses, the PCR and TMA techniques are excellent methods to 
validate the ‘key’-markers from these DNA microarray experiments in large 









In chapters 3 and 4, tissue microarrays are used to evaluate the prognostic 
significance of a candidate biomarker: the membrane-associated glycoprotein 
MUC1. The effects of this protein in breast cancer prognosis are conflicting 
as both positive and negative associations between MUC1 expression and 
tumour differentiation and outcome have been found. We applied a novel 
scoring system for MUC1 which takes the location of MUC1 expression 
in the cell into account. Five predefined MUC1 expression patterns were 
recognized: expression on the entire cell membrane, apical expression, 
focal cytoplasmic expression, diffuse cytoplasmic expression and inside-out 
expression. In chapter 3 this scoring system was applied to a series of 87 
ductal in-situ carcinomas (DCIS). Only four of the five recognized expression 
patterns of MUC1 were seen in DCIS. The inside-out pattern, which is specific 
for micropapillary carcinoma was not seen. A difference was seen between 
expression of MUC1 on the membrane of the tumour cells and expression in 
the cytoplasm. Cytoplasmic expression of MUC1 was associated with a more 
aggressive biological profile (higher grade, larger lesion size and Her2/neu 
overexpression) and with local recurrence. This suggests that the localization 
of MUC1 expression to some extent also reflects the extent of tumour cell 
differentiation. 
In chapter 4 the MUC1 scoring system was applied to a series of 243 
invasive ductal carcinomas. MUC1 apical membrane expression was associated 
with smaller tumours, lower tumour grade, progesterone expression and 
increased overall survival, suggesting that this expression pattern, which is 
also seen in normal ducts, implies better tumour differentiation. MUC1 diffuse 
cytoplasmic expression was associated with Cyclin D1 positivity, and increased 
relapse free survival. Although the intracellular routing of MUC1 molecules 
in this pattern is incorrect (normally MUC1 is expressed at the cellular 
membrane), no differences in tumour grade or size were found. This might 
be explained by the common combination of apical- and diffuse cytoplasmic 
MUC1 expression. Indeed in a subgroup analysis showed that strict cytoplasmic 
expression of MUC1 was associated with clinico-pathological factors related 
to worse outcome. MUC1 negative tumours were associated with ER, PR and 









of both decreased RFS and OS. This association was independent of the more 
‘classical’ prognostic factors. 
In chapters 5 and 6, the tissue microarray approach was used for studying 
differences between interval and screen-detected invasive and in situ 
ductal carcinomas. For DCIS the introduction of the breast cancer screening 
programme led to an increased incidence, being approximately 20% of all 
malignant lesions. Some authors suggest that at least part of the DCIS found in 
the screening programme should be considered as overdiagnosis, because DCIS 
will not always progress to an invasive carcinoma and part of the DCIS that 
do progress to an invasive carcinoma will not lead to a clinically detectable 
tumour in a patients lifetime, because the patient will die of competing causes 
of death before it becomes clinically apparent. In chapter 5 a series of screen 
detected DCIS are compared to DCIS clinically detected in the interval between 
two screening moments (interval DCIS). Screen-detected DCIS more often 
shows Her2 overexpression suggesting that screen-detected DCIS is biologically 
more aggressive than interval DCIS and should therefore not be considered as 
overdiagnosis. 
For invasive ductal carcinoma the screening programme has also led to a 
decline in the rate of advanced breast carcinomas and breast cancer mortality. 
However, a number of women still present with a clinically symptomatic 
breast carcinoma between two screening moments, a so-called interval 
carcinoma. In participants in the Dutch Breast Cancer Screening Programme, 
36% of the tumours emerge as interval carcinomas. In chapter 6 the clinico-
pathological data and expression of well validated biological markers for 
tumour aggressiveness were compared in ‘true’ interval carcinomas versus 
screen detected- and missed carcinomas (carcinomas clinically appearing 
as interval carcinomas, that were in retrospect visible on the screening 
mammogram), hypothesizing that ‘true’ interval carcinomas express more 
parameters associated with aggressive tumour behaviour. Interval carcinomas 
were five times more often larger sized (>2 cm). This difference might be 
explained by radiological factors (e.g. the density of the breast tissue or lack of 
microcalcifications) or tumour growth rate. However none of the radiological- or 









groups. In univariate analysis screen-detected tumours more often showed 
oestrogen receptor expression. The results of this study therefore suggest that 
interval carcinomas are not a biologically more aggressive group of tumours, 
but that a part of the tumours found in the screening are small biologically 
indolent tumours for which it is debatable whether they would have led to a 
clinically symptomatic breast carcinoma in a patient’s lifetime.
In chapter 7, tissue microarrays were used to test the robustness of 
HER2 testing using different antibodies as well as in situ hybridization. HER2 
overexpression in breast cancer is associated with worse clinical outcome. 
Treatment with anti-Her2/neu monoclonal antibody trastuzumab leads to a 
reduction in mortality and recurrence, only in patients with Her2/neu-positive 
breast cancer. However, trastuzumab therapy is an expensive treatment 
(approximately €37,500,- /year /patient) and can lead significant cardiotoxicity 
in a small minority of patients. Because of the high treatment costs and the 
efficacy in HER2 positive tumours only, uncompromised, robust and reliable 
HER2-testing is required. To select patients for anti-Her2 based therapy 
immunohistochemistry is commonly performed as a first step to assess 
Her2 status. It is known that interobserver and interlaboratory variability 
can compromise the assessment of Her2/neu6-9. A new anti-Her2 rabbit 
monoclonal antibody (4B5) was compared to the commonly used CB11 anti-
Her2 mouse monoclonal antibody using both fluorescent- and chromogenic 
in situ hybridisation methods as a reference. 4B5 staining was more distinct 
and showed less aspecific cytoplasmic background staining, which led to 
a more than 50% reduction of the number of 2+ scores for 4B5 compared 
to CB11. This might lead to a reduction in the number of additional in situ 
hybridisation tests and might therefore lead to a cost reduction. Although the 
study was well powered we found no significant differences in sensitivity, 
specificity, predictive values and interobserver concordance between 4B5 
and CB11. However there was a trend towards a higher specificity for 4B5 
and a trend towards an increased interobserver concordance for 4B5. These 
results therefore validate the 4B5 antibody for the assessment of HER2 
expression status and suggest that it provides more robust staining results 









to CB11. However, for tumours with a 2+ score additional gene amplification 
measurement using in situ hybridisation remains necessary.
In conclusion the tissue microarray technique can well be used to validate 
‘key’ markers from genome wide arraying studies in larger cohorts and may 
aid to the development of clinically applicable prognostic scores that are able 











Mammacarcinoom is de meest voorkomende maligniteit onder westerse 
vrouwen. ‘Klassieke’ prognostische indicatoren zoals tumorgrootte, tumorgraad 
en de expressie van hormoonreceptoren (ER en PR) en de HER2/neu receptor 
zijn goede voorspellers van uitkomst in grote groepen patiënten met 
mammacarcinoom. De uitkomst van een individuele patiënt valt echter slecht 
te voorspellen met behulp van deze indicatoren. In de afgelopen jaren zijn vele 
microarray-technieken geïntroduceerd. Deze technieken maken het mogelijk de 
expressie van vele genen of eiwitten in een patiënt te onderzoeken. Een van 
deze microarray-technieken is de tissue microarray (TMA)-techniek. Met behulp 
van deze techniek kan tumormateriaal van maximaal 300 patiënten in een 
paraffineblokje verzameld worden. Dit maakt het mogelijk om snel en efficiënt 
de expressie van een eiwit in grote series patiënten te testen. Het doel van 
dit proefschrift, zoals in hoofdstuk 1 geformuleerd, was om de toepasbaarheid 
van de tissue microarray-techniek in de evaluatie van nieuwe prognostische en 
predictieve eiwitmarkers voor het mammacarcinoom te onderzoeken.
In hoofdstuk 2 wordt een overzicht gegeven van de meest gebruikte 
microarray-technieken (oligo-/cDNA array, CGH arrays, PCR array en tissue 
microarrays). Deze technieken worden gebruikt om markers te identificeren 
die geassocieerd zijn met tumorprogressie (ontwikkeling van metastasen, 
een lokaal recidief of kanker-gerelateerd overlijden). Oligo-/cDNA arrays zijn 
de meest gebruikte microarrays en maken het mogelijk tot 50000 genen in 
een experiment te onderzoeken. Elk experiment levert een genprofiel op 
van een testsample. Deze technieken zijn zeer kostbaar (een Mammaprint 
experiment kost €2.675,-) en dusdanig complex dat het alleen maar mogelijk 
is deze technieken te gebruiken in relatief kleine studiegroepen. PCR- en TMA-
technieken zijn daarentegen goed toepasbaar in grote studiegroepen, maar 
hebben als nadeel dat er slechts één gen of eiwit per experiment onderzocht 
kan worden. Daarom kunnen de verschillende microarray-technieken heel 
goed complementair aan elkaar zijn: DNA- microarray-technieken kunnen goed 
gebruikt worden om hypotheses te genereren. PCR en TMA daarentegen zijn 
goede methodes om de belangrijkste uitkomsten van deze DNA- microarray-










In de hoofdstukken 3 en 4 werd de TMA-techniek gebruikt om 
de prognostische significantie van het celmembraan-geassocieerde 
glycoproteïne MUC1 te onderzoeken. De rol van dit eiwit in de prognose 
van het mammacarcinoom zijn tegenstrijdig in de literatuur. Zowel positieve 
als negatieve associaties tussen MUC1-expressie en tumordifferentiatie 
en uitkomst zijn beschreven. In deze hoofdstukken wordt een nieuw 
scoringssysteem voor MUC1 toegepast. Dit scoringssysteem houdt rekening met 
de lokatie van de MUC1-expressie. Vijf vooraf gedefinieerde expressiepatronen 
werden herkend: expressie op de gehele celmembraan, apicale expressie, 
focale cytoplasmatische expressie, diffuse cytoplasmatische expressie en 
inside-out expressie. In hoofdstuk 3 wordt dit scoringssysteem toegepast op 
een serie van 87 ductale carcinomen in situ (DCIS). Slechts vier van de vijf 
beschreven patronen worden herkend in DCIS. Het inside-out patroon, dat 
specifiek is voor invasief micropapillair carcinoom, werd niet aangetroffen. 
Cytoplasmatische expressie van MUC1 was in DCIS geassocieerd met een 
agressiever tumorbiologisch profiel (hogere tumorgraad, grotere laesies en 
HER2/neu-overexpressie) en met het ontstaan van lokale recidieven. Dit 
suggereert dat de locatie van MUC1 tot op zekere hoogte een afspiegeling is 
van de mate van tumorceldifferentiatie.
In hoofdstuk 4 werd het MUC1 scoring systeem toegepast op een serie van 
243 invasief ductale carcinomen. Apicale MUC1-expressie was geassocieerd 
met kleinere tumoren, lagere tumorgraad, PR-expressie en langere overall 
survival. Dit suggereert dat dit expressiepatroon, zoals ook gezien wordt in 
normale ducti, past bij een betere tumordifferentiatie. Diffuse cytoplasmatische 
expressie van MUC1 was geassocieerd met cycline D1-expressie en ziektevrije 
overleving. Hoewel de intracellulaire routing van MUC1- moleculen niet correct 
is werden geen verschillen gevonden in tumorgraad en -grootte. Dit verschil 
kan wellicht worden verklaard door de veelvoorkomende combinatie van 
apicale MUC1-expressie en cytoplasmatische MUC1-expressie. In een subgroep 
analyse waarbij er gekeken werd naar strikte cytoplasmatische expressie 
werden associaties met clinico-pathologische factoren gerelateerd aan 









waren geassocieerd met ER-, PR- en Cycline D1-negativiteit. MUC1 was een 
onafhankelijke voorspeller voor kortere ziektevrije en totale overleving.
In de hoofdstukken 5 en 6 werd de tissue microarray techniek gebruikt 
om verschillen tussen interval- en screen-detected mammatumoren te 
onderzoeken. De introductie van het bevolkingsonderzoek borstkanker heeft 
geleid tot hogere incidentiecijfers van DCIS. Op dit moment zijn ongeveer 20% 
van de maligne laesies ontdekt bij het bevolkingsonderzoek DCIS. Sommige 
auteurs suggereren dat tenminste een deel van deze laesies beschouwd dient 
te worden als overdiagnostiek, omdat DCIS niet altijd uitgroeit tot een invasief 
carcinoom en dat een deel van de tumoren die uiteindelijk uitgroeit tot een 
invasieve tumor niet klinisch detecteerbaar wordt gedurende het leven van 
een patiënt, omdat deze voordat het een klinisch dectecteerbare tumor wordt 
zal komen te overlijden aan een andere doodsoorzaak. In hoofdstuk 5 werd 
een serie screen-detected-DCIS vergeleken met een serie DCIS welke klinisch 
ontdekt werd tussen twee screeningsmomenten (interval-DCIS). Screen-
detected-DCIS laat meer HER2/neu-expressie zien. Dit suggereert dat screen-
detected-DCIS tumorbiologisch agressiever is dan interval-DCIS en dat het 
daarom niet als overdiagnostiek beschouwd dient te worden. 
Voor invasieve tumoren heeft de introductie van het bevolkingsonderzoek 
geleid tot een afname van het aantal vergevorderde mammacarcinomen en 
de mortaliteit van borstkanker. Er zijn echter nog steeds vrouwen die zich 
presenteren met een interval-carcinoom, een klinisch symptomatische tumor 
die ontdekt wordt in de periode tussen twee screeningsmomenten. 36% 
van de tumoren die gevonden worden in patiënten die deelnemen aan het 
bevolkingsonderzoek worden ontdekt als een intervalcarcinoom. In hoofdstuk 
6 worden goed gevalideerde tumorbiologische markers vergeleken tussen 
‘ware’ interval carcinomen en tumoren gevonden in het bevolkingsonderzoek 
en tumoren gemist in het bevolkingsonderzoek. De hypothese hierbij was 
dat ‘ware’ interval carcinomen meer parameters laten zien die geassocieerd 
zijn met agressiever tumorbiologisch gedrag. In deze studie hadden interval-
carcinomen vijf keer zo vaak een tumordiameter van 2 cm of groter. Dit verschil 
kan wellicht verklaard worden door radiologische factoren (bijvoorbeeld de 









de groeisnelheid van de tumor. Echter: geen van de radiologische parameters 
of parameters voor tumorgroeisnelheid verschilde tussen de beide groepen. 
In univariate analyse waren screen-detected-tumoren vaker ER-positief. Dit 
suggereert dat interval-carcinomen niet agressiever zijn dan tumoren ontdekt 
bij het bevolkingsonderzoek, maar dat dat een deel van de tumoren ontdekt 
bij het bevolkingsonderzoek klein en tumorbiologisch somnolent zijn. 
In hoofdstuk 7 werden TMA’s gebruikt om verschillende antilichamen en 
in-situ hybridisatie methoden voor Her2/neu te testen. Her2/neu-overexpressie 
bij mammacarcinoom is geassocieerd met een slechtere prognose. Behandeling 
met het anti-Her2/neu-monoclonale antilichaam trastuzumab leidt tot een 
reductie van mortaliteit en het aantal recidieven. Dit is echter alleen het 
geval bij patiënten met Her2/neu-positieve mammacarcinoom. Daarnaast 
is trastuzumab een zeer kostbare therapie (ongeveer €37.500,- /jaar /
patiënt) en kan het in een klein deel van de patiënten cardiotoxiciteit geven. 
Om de juiste patiënten voor therapie te kunnen selecteren is robuuste 
en betrouwbare Her2/neu-diagnostiek noodzakelijk. Immunohistochemie 
wordt meestal als een eerste stap in de Her2/neu-diagnostiek gebruikt. Het 
is bekend dat immunohistochemie kan lijden onder interbeoordelaar- en 
interlaboratorium variabiliteit. In dit hoofdstuk werd een nieuw anti-Her2/
neu-monoclonaal antilichaam, opgewekt in konijnen, getest en vergeleken met 
een veelgebruikt antilichaam tegen Her2/neu, opgewekt in muizen, waarbij 
fluorescente- en chromogene in-situ hybridisatie als referentiewaarden werden 
gebruikt. De 4B5 kleuring was meer uitgesproken en liet minder aspecifieke 
achtergrondkleuring zien. Hierdoor nam het aantal 2+ scores af met meer dan 
50% in vergelijking met de CB11 kleuring. In de praktijk kan het gebruik van dit 
antilichaam wellicht leiden tot een reductie van het aantal in-situ hybridisaties 
en daar aan gekoppeld een kostenreductie. Ondanks een goede power van 
de studie werden geen significante verschillen gevonden in sensitiviteit, 
specificiteit, voorspellende waardes en interbeoordelaar variabiliteit tussen 
de twee vergeleken antilichamen. Er waren echter wel trends voor een hogere 
specificiteit en een toegenomen interbeoordeelaar-concordantie voor 4B5. De 
resultaten van deze studie valideren het 4B5 antilichaam in de Her2/neu-status 
bepaling. Er zijn aanwijzingen dat 4B5 robuuster is en mogelijk een reductie 









Voor tumoren met een 2+ immunohistochemie score blijft in-situ hybridisatie 
echter noodzakelijk.
De conclusie van dit proefschrift is dat de tissue microarray-techniek 
goed gebruikt kan worden om de belangrijkste markers die uit genoom-
brede arraying studies naar voren zijn gekomen te testen in grotere 
onderzoeksgroepen en dat deze techniek derhalve kan bijdragen aan de 
ontwikkeling van klinisch toepasbare prognostische scores die het mogelijk 
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Zeven en een half jaar geleden kwam ik op de afdeling Pathologie van 
het UMCG om er een wetenschappelijke stage te doen bij Jelle Wesseling en 
Truuske de Bock. Samen met Jaap de Vries had ik enig onderzoek verricht aan 
de sentinel node procedure bij het mammacarcinoom, en ik had bedacht dat 
het leuk zou zijn een iets meer basale wetenschappelijke stage te doen. Ik 
kon aansluiten bij het onderzoek dat Marnix de Roos verrichtte naar ductaal 
carcinomen in situ. We gingen daar een (in die tijd nog) revolutionaire techniek 
van tissue microarrays voor gebruiken. Samen met Tineke van der Sluis en Inge 
Plateel ging ik een dag naar het NKI/AVL om de techniek te leren. Ed Schuuring 
dacht mee over de tumorbiologische aspecten. We verzamelden veel data 
waarover ik een scriptie schreef.
Hoe het verder ging…
Na wat omzwervingen bij de chirurgie zag ik het licht en besloot ik te 
solliciteren voor de opleiding Pathologie. Ondertussen bleek dat de hoeveelheid 
data die ik had verzameld tijdens mijn wetenschappelijke stage genoeg zou 
kunnen zijn om uiteindelijk op te promoveren. Derhalve werd Harry Hollema 
uiteindelijk zowel mijn opleider als ook mijn promotor. Mijn onderzoekstijd 
is eigenlijk mijn opleidingstijd en die is prettig gekleurd door mede-AIOS, 
opleiders, analisten en vele andere medewerkers (zeker ook in Leeuwarden 
en Zwolle). Ook waren er zo nu en dan studenten, waarvan ik Nick Zwartjes 
wil noemen, die door middel van hun wetenschappelijke stage een bijdrage 
hebben geleverd aan dit proefschrift.
De afronding…
Uiteindelijk bleek ik tussen alle bedrijven door genoeg geschreven 
te hebben om er een proefschrift van te kunnen maken. De heren Den 
Heeten, Verbeek en Van de Vijver waren zo vriendelijk plaats te nemen in 
de beoordelingscommissie. Tafie en Gerben zijn bereid mij van mentale 
en praktische ondersteuning te voorzien in de voorbereiding en tijdens 









Ondertussen op de achtergrond…
Heit en Conny, Tafie, Jelmer en Hidde, Heby en de rest van de Wijbrandi-
clan, en vrienden: veel van jullie zullen niet gesnapt hebben hoe het nou 
precies zat: opleiding en promoveren. Hoort dat bij elkaar, heeft het iets te 
maken met afstuderen? En dan hadden we het nog niet eens over de inhoud. 
Het was allemaal ook maar verwarrend. Het belangrijkste is dat het nu allemaal 
klaar is. Lieve Tera, meer nog dan ikzelf wist jij de zaken altijd te relativeren. 
Dankzij jou sta ik nog steeds nuchter met beide benen in de Groninger klei. 
Allemaal ontzettend bedankt!
